[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1682
1. Menghini R, Menini S, Amoruso R, Fiorentino L, Casagrande V, Marzano V, Tornei F, Bertucci P, Iacobini C, Serino M, Porzio O, Hribal ML, Folli F, Khokha R, Urbani A, Lauro R, Pugliese G, Federici M: Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology; 2009 Feb;136(2):663-72.e4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice.
  • Decreased expression of tissue inhibitor of metalloproteinase 3 (Timp3) is a catalyst for insulin resistance and inflammation.
  • Timp3 is a natural inhibitor of matrix metalloproteinases, tumor necrosis factor-alpha-converting enzyme (TACE), and vascular endothelial growth factor receptor 2, and therefore could affect signaling processes involved in inflammation and angiogenesis.
  • METHODS: We assessed the effects of Timp3 on inflammation, tissue remodeling, and intermediary metabolism in mice, under conditions of environmental stress (high-fat diet), genetic predisposition to insulin resistance (insulin receptor [Insr] haploinsufficiency), and varying levels of inflammation (Timp3 or Tace deficiencies).
  • RESULTS: Insr(+/-)Timp3(-/-) mice showed a higher degree of adipose and hepatic inflammation compared with wild-type, Insr(+/-), Timp3(-/-), and Insr(+/-)Tace(+/-) mice.
  • In particular, the Insr(+/-)Timp3(-/-) mice developed macrovesicular steatosis and features of severe nonalcoholic fatty liver disease, including lobular and periportal inflammation, hepatocellular ballooning, and perisinusoidal fibrosis.
  • These were associated with increased expression of inflammatory and steatosis markers, including suppressor of cytokine signaling 3 and stearoyl CoA desaturase 1, in both liver and adipose tissue.
  • CONCLUSIONS: Timp3, possibly through its regulation of TACE, appears to have a role in the pathogenesis of fatty liver disease associated with obesity.
  • [MeSH-major] Fatty Liver / genetics. Panniculitis / genetics. Tissue Inhibitor of Metalloproteinase-3 / genetics
  • [MeSH-minor] ADAM Proteins / deficiency. ADAM Proteins / metabolism. ADAM17 Protein. Adipose Tissue, White / metabolism. Animals. Dietary Fats / metabolism. Dietary Fats / pharmacology. Disease Models, Animal. Genetic Predisposition to Disease / genetics. Insulin Resistance / genetics. Liver Cirrhosis / genetics. Liver Cirrhosis / metabolism. Mice. Mice, Inbred C57BL. Mice, Knockout. Obesity / metabolism. Stearoyl-CoA Desaturase / metabolism. Suppressor of Cytokine Signaling 3 Protein. Suppressor of Cytokine Signaling Proteins / metabolism

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027012.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP08065
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Socs3 protein, mouse; 0 / Suppressor of Cytokine Signaling 3 Protein; 0 / Suppressor of Cytokine Signaling Proteins; 0 / Tissue Inhibitor of Metalloproteinase-3; EC 1.14.19.1 / Scd1 protein, mouse; EC 1.14.19.1 / Stearoyl-CoA Desaturase; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.86 / ADAM17 Protein; EC 3.4.24.86 / Adam17 protein, mouse
  •  go-up   go-down


2. Bertola A, Bonnafous S, Cormont M, Anty R, Tanti JF, Tran A, Le Marchand-Brustel Y, Gual P: Hepatocyte growth factor induces glucose uptake in 3T3-L1 adipocytes through A Gab1/phosphatidylinositol 3-kinase/Glut4 pathway. J Biol Chem; 2007 Apr 6;282(14):10325-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adipose tissue is a source of hepatocyte growth factor (HGF), and circulating HGF levels have been associated with elevated body mass index in human.
  • However, the effects of HGF on adipocyte functions have not yet been investigated.
  • In adipocytes rendered insulin-resistant by a long-lasting tumor necrosis factor alpha treatment, the protein level of Gab1 was strongly decreased, and HGF-stimulated PKB activation and glucose uptake were also altered.
  • These data provide the first evidence that in vitro HGF promotes glucose uptake through a Gab1/PI 3-kinase/PKB/AS160 pathway which was altered in tumor necrosis factor alpha-treated adipocytes.
  • [MeSH-minor] Animals. Cell Line. GTPase-Activating Proteins / metabolism. Hypoglycemic Agents / pharmacology. Insulin / pharmacology. Insulin Receptor Substrate Proteins. Insulin Resistance. Mice. Mice, Obese. Protein Transport / drug effects. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins c-met / biosynthesis. Thiazolidinediones / pharmacology. Time Factors. Tumor Necrosis Factor-alpha / pharmacology

  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284447.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GTPase-Activating Proteins; 0 / Gab1 protein, mouse; 0 / Glucose Transporter Type 4; 0 / Hypoglycemic Agents; 0 / IRS1 protein, human; 0 / Insulin; 0 / Insulin Receptor Substrate Proteins; 0 / Irs1 protein, mouse; 0 / Phosphoproteins; 0 / Slc2a4 protein, mouse; 0 / Tbc1d4 protein, mouse; 0 / Thiazolidinediones; 0 / Tumor Necrosis Factor-alpha; 2295-31-0 / 2,4-thiazolidinedione; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; IY9XDZ35W2 / Glucose
  •  go-up   go-down


3. Sadri H, Bruckmaier RM, Rahmani HR, Ghorbani GR, Morel I, van Dorland HA: Gene expression of tumour necrosis factor and insulin signalling-related factors in subcutaneous adipose tissue during the dry period and in early lactation in dairy cows. J Anim Physiol Anim Nutr (Berl); 2010 Oct;94(5):e194-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression of tumour necrosis factor and insulin signalling-related factors in subcutaneous adipose tissue during the dry period and in early lactation in dairy cows.
  • Gene expression of adipose factors, which may be part of the mechanisms that underlie insulin sensitivity, were studied in dairy cows around parturition.
  • In the adipose tissue samples, mRNA was quantified by real-time reverse transcription polymerase chain reaction for tumour necrosis factor alpha (TNFα), insulin-independent glucose transporter (GLUT1), insulin-responsive glucose transporter (GLUT4), insulin receptor, insulin receptor substrate 1 (IRS1), insulin receptor substrate 2 (IRS2), regulatory subunit of phosphatidylinositol-3 kinase (p85) and catalytic subunit of phosphatidylinositol-3 kinase.
  • Blood plasma was assayed for concentrations of glucose, β-hydroxybutyric acid, non-esterified fatty acids (NEFA) and insulin.
  • Gene expression changes were observed, but there were no changes in TNFα concentrations, which may indicate its local involvement in catabolic adaptation of adipose tissue.
  • [MeSH-major] Cattle / physiology. Gene Expression Regulation / physiology. Insulin / metabolism. Lactation / metabolism. Subcutaneous Fat / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Verlag GmbH.
  • (PMID = 20579185.001).
  • [ISSN] 1439-0396
  • [Journal-full-title] Journal of animal physiology and animal nutrition
  • [ISO-abbreviation] J Anim Physiol Anim Nutr (Berl)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glucose Transport Proteins, Facilitative; 0 / Insulin; 0 / Insulin Receptor Substrate Proteins; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; EC 2.7.10.1 / Receptor, Insulin
  •  go-up   go-down


Advertisement
4. Li MY, Lee TW, Yim AP, Chen GG: Function of PPARgamma and its ligands in lung cancer. Crit Rev Clin Lab Sci; 2006;43(2):183-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • is highly expressed in adipose tissue and has a dominant regulatory role in adipocyte differentiation.
  • is expressed in multiple tissues such as the breast, colon, lung, ovary, and placenta.
  • activation has been shown to be anti-proliferative by virtue of its differentiation-promoting effect, suggesting that activation of PPAR?
  • may be useful in slowing or arresting the proliferation of de-differentiated tumor cells.
  • on the inhibition of tumor cell growth.
  • gene transcription, and recent developments in the discovery of its biological functions on growth inhibition of lung tumors.
  • [MeSH-major] Lung Neoplasms / drug therapy. Lung Neoplasms / physiopathology. PPAR gamma / metabolism. PPAR gamma / pharmacology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517422.001).
  • [ISSN] 1040-8363
  • [Journal-full-title] Critical reviews in clinical laboratory sciences
  • [ISO-abbreviation] Crit Rev Clin Lab Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / PPAR gamma; 0 / Transcription Factors; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Number-of-references] 99
  •  go-up   go-down


5. Tisdale MJ: Mechanisms of cancer cachexia. Physiol Rev; 2009 Apr;89(2):381-410
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Up to 50% of cancer patients suffer from a progressive atrophy of adipose tissue and skeletal muscle, called cachexia, resulting in weight loss, a reduced quality of life, and a shortened survival time.
  • Anorexia often accompanies cachexia, but appears not to be responsible for the tissue loss, particularly lean body mass.
  • Loss of adipose tissue is due to an increased lipolysis by tumor or host products.
  • Tumor factors such as proteolysis-inducing factor and host factors such as tumor necrosis factor-alpha, angiotensin II, and glucocorticoids can all induce muscle atrophy.
  • Knowledge of the mechanisms of tissue destruction in cachexia should improve methods of treatment.
  • [MeSH-major] Cachexia / physiopathology. Neoplasms / physiopathology
  • [MeSH-minor] Adipose Tissue / metabolism. Adipose Tissue / pathology. Atrophy. Energy Metabolism / physiology. Humans. Muscle, Skeletal / metabolism. Muscle, Skeletal / pathology

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342610.001).
  • [ISSN] 0031-9333
  • [Journal-full-title] Physiological reviews
  • [ISO-abbreviation] Physiol. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 299
  •  go-up   go-down


6. Agarwal AK, Garg A: Enzymatic activity of the human 1-acylglycerol-3-phosphate-O-acyltransferase isoform 11: upregulated in breast and cervical cancers. J Lipid Res; 2010 Aug;51(8):2143-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At least, mutations in one isoform, AGPAT2, cause near complete loss of adipose tissue in humans.
  • The AGPAT11 efficiently uses C18:1 LPA as acyl acceptor and C18:1 fatty acid as an acyl donor.
  • Expression of AGPAT11 mRNA was significantly upregulated in human breast, cervical, and colorectal cancer tissues, indicating its adjuvant role in the progression of these cancers.


7. Kurita H, Kamata T, Koike T, Kobayashi H, Kurashina K: Intraoperative tissue staining of invaded oral carcinoma. Pathol Oncol Res; 2008 Dec;14(4):461-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative tissue staining of invaded oral carcinoma.
  • The purpose of this study was to assess the ability of intraoperative tissue staining with consecutive application of 0.4% indigo carmine and 0.5% Congo red to demonstrate the extent and border of oral carcinoma invasion.
  • Once the oral tumor was resected, a vertical section of surgical specimen was taken from the central part of the tumor.
  • The extent and border of the invaded carcinoma were assessed on digital microscopic examination with tissue staining.
  • Tissue staining produced a brown-black stain on normal muscle, connective, and salivary tissues but not tumor and epithelial tissues.
  • It clearly demonstrated the extent and border of tumor invasion in 13 of 17 patients (76.5%); however, detection of remnant vital tumor cells in scar tissue after neoadjuvant chemotherapy, and distinction between the tumor and adipose tissue scattered in the muscle tissue was difficult.
  • The results of this study showed that intraoperative tissue staining was a possible method in demonstrating the extent and border of carcinoma deeply invaded in the soft tissue and selecting the site for additional frozen section analysis, although the method needed some refinement.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / surgery. Mouth Neoplasms / pathology. Mouth Neoplasms / surgery. Neoplasm Staging / methods. Staining and Labeling / methods

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trans Am Acad Ophthalmol Otolaryngol. 1974 Jan-Feb;78(1):ORL49-53 [4813646.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2956-60 [7139587.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Aug;61(8):890-4; discussion 895-7 [12905439.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Apr;32(2):152-8 [12729775.001]
  • [Cites] Can J Gastroenterol. 1999 Jun;13(5):423-9 [10377475.001]
  • [Cites] Baillieres Best Pract Res Clin Gastroenterol. 1999 Apr;13(1):11-9 [11030630.001]
  • [Cites] Am J Surg. 2006 Jan;191(1):84-8 [16399112.001]
  • [Cites] Am J Surg. 1978 Oct;136(4):525-8 [707736.001]
  • (PMID = 18575826.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Vick MM, Murphy BA, Sessions DR, Reedy SE, Kennedy EL, Horohov DW, Cook RF, Fitzgerald BP: Effects of systemic inflammation on insulin sensitivity in horses and inflammatory cytokine expression in adipose tissue. Am J Vet Res; 2008 Jan;69(1):130-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of systemic inflammation on insulin sensitivity in horses and inflammatory cytokine expression in adipose tissue.
  • OBJECTIVE: To determine whether an inflammatory challenge induces insulin resistance in horses and examine possible contributions of adipose tissue to inflammatory cytokine production.
  • PROCEDURES: Lipopolysaccharide (0.045 mug/kg, IV) or saline solution was administered, and insulin sensitivity was determined by means of the hyperinsulinemic, euglycemic clamp procedure or an adipose tissue biopsy was performed.
  • Adipose tissue samples were collected, and mature adipocytes were obtained.
  • Interleukin-1, interleukin-6, and tumor necrosis factor A expression in blood, adipose tissue, and adipocytes was quantified with a real-time, reverse transcriptase- PCR assay.
  • Increased cytokine expression was observed in blood and adipose tissue following administration of lipopolysaccharide, and adipocytes and preadipocytes stimulated with lipopolysaccharide stained positive for tumor necrosis factor A.
  • Expression of interleukin-1, interleukin-6, and tumor necrosis factor A was detected in preadipocytes stimulated with lipopolysaccharide, and interleukin-6 and tumor necrosis factor A were detected in mature adipocytes stimulated with lipopolysaccharide.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that insulin resistance develops following systemic inflammation in horses and suggested that adipose tissue may contribute to this inflammatory response.
  • [MeSH-major] Adipose Tissue / metabolism. Cytokines / metabolism. Gene Expression Regulation / physiology. Horse Diseases / chemically induced. Insulin Resistance / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18167098.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


9. Kawasaki M, Miura Y, Yagasaki K: Effects of sulfur amino acids, L: -methionine, L: -cystine and L: -cysteine on lipoprotein lipase and hormone-sensitive lipase in differentiated mouse 3T3-L1 adipocytes. Cytotechnology; 2010 Jul;62(3):225-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rats subcutaneously implanted with AH109A hepatoma cells show hyperlipidemia with high concentrations of serum triglyceride and nonesterified fatty acid, suppression of lipoprotein lipase (LPL), and elevation of hormone-sensitive lipase (HSL) activities during the growth of the hepatoma.
  • The adipocytes were incubated with various concentrations of Met, Cys or L: -cysteine (CysH) in the absence or presence of tumor necrosis factor-alpha (TNF-alpha).
  • In the absence of TNF-alpha, Met, Cys and CysH did not change the LPL activity.
  • Some of these effects of sulfur amino acids were different between LPL and HSL, between the absence and the presence of TNF-alpha, and between 3T3-L1 adipocytes and the adipose tissue from rats.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biosci Biotechnol Biochem. 2004 Jan;68(1):72-8 [14745166.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Feb;79(3):912-6 [7038689.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2009 Mar;19(3):218-25 [18718745.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Lipid Res. 1989 Apr;30(4):579-85 [2754338.001]
  • [Cites] Nucleic Acids Res. 1985 Mar 11;13(5):1431-42 [2987824.001]
  • [Cites] J Nutr Sci Vitaminol (Tokyo). 1986 Dec;32(6):643-51 [3473191.001]
  • [Cites] Arch Biochem Biophys. 1986 Dec;251(2):738-46 [3800396.001]
  • [Cites] Cancer Res. 1972 Aug;32(8):1756-60 [4625512.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Feb;78(2):732-6 [6262767.001]
  • [Cites] Lipids. 1995 May;30(5):431-6 [7637563.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Lipid Res. 1976 Sep;17(5):536-41 [9464.001]
  • [Cites] Metabolism. 1979 Jan;28(1):30-40 [759824.001]
  • [Cites] Science. 1987 Mar 27;235(4796):1638-41 [3823907.001]
  • [Cites] Lipids. 1985 Jul;20(7):420-4 [4033362.001]
  • [Cites] Cancer Res. 1970 Sep;30(9):2420-30 [5529116.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(2):158-61 [18459552.001]
  • (PMID = 20628900.001).
  • [ISSN] 0920-9069
  • [Journal-full-title] Cytotechnology
  • [ISO-abbreviation] Cytotechnology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2932907
  •  go-up   go-down


10. Wassel Fyr CL, Kanaya AM, Cummings SR, Reich D, Hsueh WC, Reiner AP, Harris TB, Moffett S, Li R, Ding J, Miljkovic-Gacic I, Ziv E, Health, Aging, Body Composition Study: Genetic admixture, adipocytokines, and adiposity in Black Americans: the Health, Aging, and Body Composition study. Hum Genet; 2007 Jun;121(5):615-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adipocytokines are a subset of cytokines produced by adipose tissue and are associated with risk of type II diabetes and atherosclerosis.
  • Levels of adipocytokines differ between Black and White Americans, even after adjustment for differences in adiposity, diseases associated with adipocytokines including type 2 diabetes and cardiovascular disease, and general socioeconomic status indicators such as income.
  • In multivariate adjusted models, the strongest associations observed were between higher European ancestry and interleukin-6 soluble receptor (IL-6 SR), C-reactive protein (CRP), and adiponectin levels, with interleukin-2 soluble receptor (IL-2 SR) and soluble tumor necrosis factor receptor II (TNF-alpha SR II) also showing more modest but significant associations.
  • [MeSH-minor] Adipose Tissue / metabolism. Aged. Cytokines / genetics. Female. Genetic Markers. Humans. Likelihood Functions. Male

  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2005 Jan;76(1):1-7 [15540159.001]
  • [Cites] Life Sci. 2000 Jun 8;67(3):291-300 [10983873.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14068-73 [16945910.001]
  • [Cites] Genetics. 2000 Jun;155(2):945-59 [10835412.001]
  • [Cites] Int J Clin Pract. 2005 Jan;59(1):102-6 [15707473.001]
  • [Cites] Arch Intern Med. 2006 Feb 13;166(3):350-6 [16476877.001]
  • [Cites] Am J Hum Genet. 2005 Jun;76(6):967-86 [15834813.001]
  • [Cites] Am J Hum Genet. 2005 Mar;76(3):463-77 [15660291.001]
  • [Cites] Am J Hum Genet. 2004 May;74(5):979-1000 [15088269.001]
  • [Cites] Genet Epidemiol. 1986;3(6):435-54 [3803913.001]
  • [Cites] Am J Hum Genet. 2004 May;74(5):965-78 [15088268.001]
  • [Cites] Ann Hum Genet. 2000 Mar;64(Pt 2):171-86 [11246470.001]
  • [Cites] Am J Hum Genet. 1997 Apr;60(4):957-64 [9106543.001]
  • [Cites] Diabetes. 2002 Apr;51(4):1131-7 [11916936.001]
  • [Cites] Nat Genet. 2005 Feb;37(2):177-81 [15665825.001]
  • [Cites] N Engl J Med. 2000 Jun 15;342(24):1792-801 [10853003.001]
  • [Cites] Am J Hum Genet. 2003 Dec;73(6):1402-22 [14631557.001]
  • [Cites] Circulation. 2003 May 20;107(19):2422-7 [12719278.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1930-5 [11344187.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2002 May;57(5):M326-32 [11983728.001]
  • [Cites] Obes Res. 2002 May;10(5):336-44 [12006632.001]
  • [Cites] Hum Genet. 2006 Jul;119(6):624-33 [16738946.001]
  • [Cites] Diabetologia. 1998 Jul;41(7):860-1 [9686931.001]
  • [Cites] Am J Hum Genet. 2004 May;74(5):1001-13 [15088270.001]
  • [Cites] Obes Res. 1999 Mar;7(2):164-9 [10102253.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Diabetes Res Clin Pract. 2006 Jun;72(3):244-50 [16377022.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1730-7 [15082700.001]
  • [Cites] Am J Clin Nutr. 2004 Sep;80(3):576-83 [15321795.001]
  • [Cites] Am J Hum Genet. 1998 Dec;63(6):1839-51 [9837836.001]
  • [Cites] Metabolism. 2004 Jan;53(1):1-3 [14681833.001]
  • [Cites] Am J Clin Nutr. 2001 Sep;74(3):295-301 [11522551.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):5044-50 [16984981.001]
  • [Cites] J Am Coll Cardiol. 2005 Aug 2;46(3):464-9 [16053959.001]
  • [Cites] Genome Biol. 2002 Jul 1;3(7):comment2007 [12184798.001]
  • [Cites] Cell Metab. 2006 Dec;4(6):465-74 [17141630.001]
  • [Cites] Hum Genet. 2006 Jan;118(5):652-64 [16283388.001]
  • [Cites] JAMA. 2001 Jul 18;286(3):327-34 [11466099.001]
  • [Cites] Obes Res. 2005 Aug;13(8):1458-65 [16129729.001]
  • [Cites] Hum Genet. 2003 Apr;112(4):387-99 [12579416.001]
  • [Cites] Circulation. 2003 Nov 11;108(19):2317-22 [14568895.001]
  • [Cites] Circulation. 2005 Jul 5;112(1):25-31 [15983251.001]
  • [Cites] Thromb Haemost. 2006 Mar;95(3):511-8 [16525580.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1113-8 [16186815.001]
  • (PMID = 17390149.001).
  • [ISSN] 0340-6717
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / N01-AG-6-2101; United States / NCI NIH HHS / CA / K22CA109351; United States / NHLBI NIH HHS / HL / T32 HL097972; United States / NIA NIH HHS / AG / N01-AG-6-2103; United States / NHLBI NIH HHS / HL / F32 HL083641-01; United States / NHLBI NIH HHS / HL / F32 HL083641; United States / NHLBI NIH HHS / HL / F32 HL083641-02; United States / Intramural NIH HHS / / ; United States / NIA NIH HHS / AG / N01-AG-6-2106; United States / NIDDK NIH HHS / DK / R21 DK068608
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines; 0 / Genetic Markers
  •  go-up   go-down


11. Ruiz E, Pozo P, Toselli L, Fernández M, Christiansen S, Lambertini R: Unusual benign paratesticular tumor in an infant mimicking rhabdomyosarcoma. Urology; 2008 Jun;71(6):1067-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual benign paratesticular tumor in an infant mimicking rhabdomyosarcoma.
  • Paratesticular tumors are extremely rare, with paratesticular rhabdomyosarcoma being the most common finding.
  • A 6-month-old boy presented with an asymptomatic, right intrascrotal mass whereby the testicle was surrounded by a friable lipomatous tumor.
  • [MeSH-major] Rhabdomyosarcoma / pathology. Testicular Diseases / pathology. Testicular Neoplasms / pathology. Xanthogranuloma, Juvenile / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538690.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Rajeswaran R, Murthy J, Chandrasekharan A, Joseph S: Case Report: Congenital infiltrating lipomatosis of face. Indian J Radiol Imaging; 2008 Nov;18(4):306-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Congenital infiltrating lipomatosis of the face is a rare condition characterized by diffuse fatty infiltration of the facial soft tissues.
  • It is a type of lipomatous tumor that is congenital in origin; it is rare and seen usually in childhood.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Radiol. 2006 Nov;36(11):1159-62 [16953375.001]
  • [Cites] Plast Reconstr Surg. 1983 Aug;72(2):158-64 [6192455.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Feb;24(2):283-6 [12591650.001]
  • [Cites] Chang Gung Med J. 2002 Mar;25(3):194-200 [12022741.001]
  • [Cites] Plast Reconstr Surg. 2001 Nov;108(6):1544-54 [11711926.001]
  • (PMID = 19774187.001).
  • [ISSN] 0971-3026
  • [Journal-full-title] The Indian journal of radiology & imaging
  • [ISO-abbreviation] Indian J Radiol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2747453
  • [Keywords] NOTNLM ; Congenital / lipomatosis
  •  go-up   go-down


13. Broch M, Ramírez R, Auguet MT, Alcaide MJ, Aguilar C, Garcia-Espana A, Richart C: Macrophages are novel sites of expression and regulation of retinol binding protein-4 (RBP4). Physiol Res; 2010;59(2):299-303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the infiltration of adipose tissue in obesity by macrophages derived from circulating monocytes and, on the other hand, the existence of a close genetic relationship between adipocytes and macrophages, we decided to examine if RBP4 is expressed in monocytes and/or primary human macrophages.
  • While we did not detect expression of RBP4 in undifferentiated monocytes, RBP4 expression became evident during the differentiation of monocytes into macrophages and was highest in differentiated macrophages.
  • Once we demonstrated the expression of RBP4 in macrophages, we checked if RBP4 expression could be regulated by inflammatory stimuli such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), or the endotoxin lipopolysaccharide (LPS).
  • We observed that while RBP4 expression was strongly inhibited by TNF-alpha and LPS, it was not affected by IL-6.

  • MedlinePlus Health Information. consumer health - Obesity.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537932.001).
  • [ISSN] 0862-8408
  • [Journal-full-title] Physiological research
  • [ISO-abbreviation] Physiol Res
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / IL6 protein, human; 0 / Interleukin-6; 0 / Lipopolysaccharides; 0 / RBP4 protein, human; 0 / RNA, Messenger; 0 / Retinol-Binding Proteins, Plasma; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


14. López Martín L, García Cardoso JV, Gómez Muñoz J, González Enguita C: Adrenal myelolipoma. Contribution of a case and bibliographic review. Arch Esp Urol; 2010 Dec;63(10):880-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal myelolipoma. Contribution of a case and bibliographic review.
  • The pathological study confirmed the diagnosis of adrenal myelolipoma.
  • CONCLUSIONS: The myelolipoma is a rare tumor composed of hematopoietic elements in different maturation stages and without histological changes, combined with mature adipose tissue in varying proportions.
  • [MeSH-major] Adrenal Gland Neoplasms. Myelolipoma

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187573.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


15. Akiyama T, Morita T, Takimoto Y, Shimada A: Lymphoepithelial thymoma characterized by proliferation of spindle cells in a Samoyed dog. J Vet Med Sci; 2009 Sep;71(9):1265-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, the mass consisted of solid proliferation of neoplastic cells with spindle nuclei and cytoplasm and a few lymphocytes, which is separated by an abundant fibrous and adipose tissue.
  • On the basis of these findings, this tumor was diagnosed as lymphoepithelial thymoma, which is morphologically similar to type A thymoma in humans.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801913.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Moloney F, Toomey S, Noone E, Nugent A, Allan B, Loscher CE, Roche HM: Antidiabetic effects of cis-9, trans-11-conjugated linoleic acid may be mediated via anti-inflammatory effects in white adipose tissue. Diabetes; 2007 Mar;56(3):574-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antidiabetic effects of cis-9, trans-11-conjugated linoleic acid may be mediated via anti-inflammatory effects in white adipose tissue.
  • Adipose tissue may be the source of insulin desensitizing proinflammatory molecules that predispose to insulin resistance.
  • This study investigated whether dietary fatty acids could attenuate the proinflammatory insulin-resistant state in obese adipose tissue.
  • The potential antidiabetic effect of cis-9, trans-11-conjugated linoleic acid (c9,t11-CLA) was determined, focusing on the molecular markers of insulin sensitivity and inflammation in adipose tissue of ob/ob C57BL-6 mice.
  • Feeding a c9,t11-CLA-enriched diet reduced fasting glucose (P < 0.05), insulin (P < 0.05), and triacylglycerol concentrations (P < 0.01) and increased adipose tissue plasma membrane GLUT4 (P < 0.05) and insulin receptor (P < 0.05) expression compared with the control linoleic acid-enriched diet.
  • Interestingly, after the c9,t11-CLA diet, adipose tissue macrophage infiltration was less, with marked downregulation of several inflammatory markers in adipose tissue, including reduced tumor necrosis factor-alpha and CD68 mRNA (P < 0.05), nuclear factor-kappaB (NF-kappaB) p65 expression (P < 0.01), NF-kappaB DNA binding (P < 0.01), and NF-kappaB p65, p50, c-Rel, p52, and RelB transcriptional activity (P < 0.01).
  • To define whether these observations were direct effects of the nutrient intervention, complimentary cell culture studies showed that c9,t11-CLA inhibited tumor necrosis factor-alpha-induced downregulation of insulin receptor substrate 1 and GLUT4 mRNA expression and promoted insulin-stimulated glucose transport in 3T3-L1 adipocytes compared with linoleic acid.
  • This study suggests that altering fatty acid composition may attenuate the proinflammatory state in adipose tissue that predisposes to obesity-induced insulin resistance.
  • [MeSH-major] Adipose Tissue, White / drug effects. Adipose Tissue, White / pathology. Hypoglycemic Agents / pharmacology. Inflammation / drug therapy. Linoleic Acids, Conjugated / pharmacology


17. Briana DD, Malamitsi-Puchner A: Intrauterine growth restriction and adult disease: the role of adipocytokines. Eur J Endocrinol; 2009 Mar;160(3):337-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrauterine growth restriction and adult disease: the role of adipocytokines.
  • Although the mechanisms controlling intrauterine growth are poorly understood, adipose tissue may play an important role in linking poor fetal growth to the subsequent development of adult diseases.
  • Adipose tissue secretes a number of hormones, called adipocytokines, important in modulating metabolism and recently involved in intrauterine growth.
  • This review aims to summarize reported findings concerning the role of adipocytokines (leptin, adiponectin, ghrelin, tumor necrosis factor (TNF), interleukin-6 (IL6), visfatin, resistin, apelin) in early life, while attempting to speculate mechanisms through which differential regulation of adipocytokines in IUGR may influence the risk for development of chronic diseases in later life.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095781.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adipokines
  • [Number-of-references] 159
  •  go-up   go-down


18. Chahal J, Chen CC, Rane MJ, Moore JP, Barati MT, Song Y, Villafuerte BC: Regulation of insulin-response element binding protein-1 in obesity and diabetes: potential role in impaired insulin-induced gene transcription. Endocrinology; 2008 Oct;149(10):4829-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue expression of IRE-BP1 is 50- to 200-fold higher in classical insulin target compared with nontarget tissues in lean animals, with a significantly reduced level of expression in the skeletal muscle and adipose tissue in obese and diabetic animals.

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1999 Nov 19;461(3):229-34 [10567702.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10105-17 [16492665.001]
  • [Cites] Mol Cell Endocrinol. 2000 Jun;164(1-2):205-18 [11026572.001]
  • [Cites] Endocr Rev. 2000 Dec;21(6):697-738 [11133069.001]
  • [Cites] Endocrinology. 2001 Mar;142(3):1041-9 [11181517.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Jun;280(6):E994-9 [11350781.001]
  • [Cites] Mol Cell Probes. 2002 Apr;16(2):99-110 [12030760.001]
  • [Cites] Obes Rev. 2001 Nov;2(4):239-54 [12119995.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45276-84 [12228231.001]
  • [Cites] J Mol Endocrinol. 2002 Dec;29(3):265-79 [12459029.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Mar;284(3):E541-8 [12556351.001]
  • [Cites] Nature. 2003 May 29;423(6939):550-5 [12754525.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36650-9 [15194686.001]
  • [Cites] Am J Physiol. 1988 Nov;255(5 Pt 1):E716-22 [3189541.001]
  • [Cites] J Biol Chem. 1990 Jul 25;265(21):12642-9 [1695633.001]
  • [Cites] J Biol Chem. 1990 Dec 5;265(34):21185-93 [1701175.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Mar 15;175(2):507-14 [2018498.001]
  • [Cites] J Biol Chem. 1994 Dec 9;269(49):30835-41 [7983014.001]
  • [Cites] Am J Physiol. 1995 Jul;269(1 Pt 1):E150-4 [7631770.001]
  • [Cites] Mol Cell Probes. 1996 Dec;10(6):427-33 [9025080.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):5024-30 [9030565.001]
  • [Cites] Endocrinology. 1997 Apr;138(4):1464-70 [9075703.001]
  • [Cites] Obes Res. 1998 Jan;6(1):69-75 [9526973.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3182-94 [9784493.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):15982-5 [10347145.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17179-83 [10358075.001]
  • [Cites] Endocrinology. 1999 Jul;140(7):3140-6 [10385407.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4761-71 [10499536.001]
  • [Cites] Diabetes. 2005 May;54(5):1314-23 [15855315.001]
  • [Cites] Trends Endocrinol Metab. 2005 May-Jun;16(4):183-9 [15860415.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):20010-20 [15753094.001]
  • [Cites] Am J Physiol. 1999 Dec;277(6 Pt 2):R1690-6 [10600915.001]
  • (PMID = 18566119.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067413; United States / NIDDK NIH HHS / DK / DK067413
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin; 0 / Insulin; 0 / Insulin-Like Growth Factor Binding Protein 1; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / RNA, Small Interfering; 67763-96-6 / Insulin-Like Growth Factor I; EC 4.2.1.3 / Iron Regulatory Protein 1
  • [Other-IDs] NLM/ PMC2582919
  •  go-up   go-down


19. Reigstad CS, Lundén GO, Felin J, Bäckhed F: Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PLoS One; 2009;4(6):e5842
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota.
  • Recent reports indicate that gut bacteria-derived lipopolysaccharide (LPS) can initiate obesity and insulin resistance in mice; however, the molecular interactions responsible for microbial regulation of host metabolism and mediators of inflammation have not been studied in detail.
  • Adipose tissue-derived SAA3 displays monocyte chemotactic activity and may play a role in metabolic inflammation associated with obesity and insulin resistance.
  • SAA3 expression was determined to be significantly augmented in adipose (9.9+/-1.9-fold; P<0.001) and colonic tissue (7.0+/-2.3-fold; P<0.05) by the presence of intestinal microbes.
  • Our data suggest that LPS, and potentially other products of the indigenous gut microbiota, might elevate cytokine expression in tissues and thus exacerbate chronic low-grade inflammation observed in obesity.
  • [MeSH-major] Adipose Tissue / metabolism. Colon / metabolism. Epithelium / metabolism. Gene Expression Regulation. Intestines / microbiology. Serum Amyloid A Protein / biosynthesis
  • [MeSH-minor] Animals. Genetic Variation. Inflammation. Lipopolysaccharides / metabolism. Macrophages / metabolism. Male. Mice. Obesity / metabolism. Signal Transduction. Tumor Necrosis Factor-alpha / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2006 Dec 21;444(7122):1022-3 [17183309.001]
  • [Cites] Nature. 2006 Dec 14;444(7121):860-7 [17167474.001]
  • [Cites] Diabetes. 2007 Jul;56(7):1761-72 [17456850.001]
  • [Cites] Diabetes. 2007 Aug;56(8):1986-98 [17519423.001]
  • [Cites] Diabetes. 2007 Sep;56(9):2260-73 [17563062.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Nov;23(6):647-54 [17906442.001]
  • [Cites] Cell Host Microbe. 2008 Apr 17;3(4):213-23 [18407065.001]
  • [Cites] Diabetes. 2008 Jun;57(6):1470-81 [18305141.001]
  • [Cites] Exp Diabetes Res. 2008;2008:230837 [18584041.001]
  • [Cites] J Cell Biochem. 2008 Aug 15;104(6):2241-7 [18452164.001]
  • [Cites] Life Sci. 2008 Sep 26;83(13-14):502-10 [18761356.001]
  • [Cites] Nat Cell Biol. 2008 Nov;10(11):1349-55 [18820689.001]
  • [Cites] Diabetes Metab Res Rev. 2008 Nov-Dec;24(8):595-603 [18756581.001]
  • [Cites] Nature. 2009 Jan 22;457(7228):480-4 [19043404.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2009 Mar;48(3):249-56 [19271298.001]
  • [Cites] J Immunol. 2000 Jan 15;164(2):966-72 [10623846.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42077-83 [11546817.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Circulation. 2004 Feb 17;109(6):726-32 [14970107.001]
  • [Cites] Endocrinology. 2004 May;145(5):2245-52 [14749357.001]
  • [Cites] Atherosclerosis. 2004 Jun;174(2):349-56 [15136066.001]
  • [Cites] J Exp Med. 1986 Dec 1;164(6):2006-17 [3783088.001]
  • [Cites] J Exp Med. 1989 May 1;169(5):1841-6 [2715765.001]
  • [Cites] Cell. 1989 Jul 28;58(2):227-9 [2665943.001]
  • [Cites] Mol Cell Biochem. 1992 Aug 18;113(2):151-69 [1518506.001]
  • [Cites] Gene. 1994 Nov 18;149(2):305-10 [7959007.001]
  • [Cites] FEMS Microbiol Lett. 1999 May 15;174(2):247-50 [10339815.001]
  • [Cites] Immunity. 1999 Jul;11(1):115-22 [10435584.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24649-56 [10455131.001]
  • [Cites] Eur J Biochem. 1999 Oct;265(2):501-23 [10504381.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15718-23 [15505215.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):99-104 [15615857.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1915-20 [15790844.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2233-9 [15623807.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5 [16033867.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):3070-9 [16493066.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):816-25 [16410796.001]
  • [Cites] PLoS Med. 2006 Jun;3(6):e287 [16737350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):979-84 [17210919.001]
  • (PMID = 19513118.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipopolysaccharides; 0 / Serum Amyloid A Protein; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2688757
  •  go-up   go-down


20. Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D: Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology; 2010 Jan;151(1):32-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
  • We show that calcitriol, the hormonally active form of vitamin D, regulates the expression of aromatase in a tissue-selective manner.
  • Calcitriol administration to immunocompromised mice bearing human BCa xenografts decreased aromatase mRNA levels in the tumors and the surrounding mammary adipose tissue but did not alter ovarian aromatase expression.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):41-7 [11850206.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Feb;80(2):203-12 [11897504.001]
  • [Cites] Pain. 2002 Jul;98(1-2):163-8 [12098628.001]
  • [Cites] J Cell Biochem. 2003 Feb 1;88(2):363-71 [12520538.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):85-92 [12650704.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):42431-7 [15297458.001]
  • [Cites] Front Biosci. 1998 Aug 6;3:d922-33 [9696881.001]
  • [Cites] Eur J Endocrinol. 2003 May;148(5):519-26 [12720534.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jun;74(6):1247-52 [1592866.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11312-6 [8248245.001]
  • [Cites] Endocrinology. 1996 May;137(5):1540-4 [8612483.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):1273-7 [8772611.001]
  • [Cites] Mol Cell Probes. 1995 Dec;9(6):453-64 [8808317.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Nov;81(11):3843-9 [8923826.001]
  • [Cites] Breast Cancer Res Treat. 1997 Jan;42(1):31-41 [9116316.001]
  • [Cites] Endocrinology. 1997 Sep;138(9):3711-8 [9275056.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):273-80 [9365201.001]
  • [Cites] Endocrinology. 1998 Apr;139(4):1684-91 [9528950.001]
  • [Cites] Breast Cancer Res Treat. 1998;49 Suppl 1:S85-91; discussion S109-19 [9797022.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2644-9 [10363987.001]
  • [Cites] Cancer Lett. 1999 Jun 1;140(1-2):27-35 [10403538.001]
  • [Cites] Toxicol Sci. 2004 Dec;82(2):443-50 [15456920.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 25;328(4):831-7 [15707954.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2809-21 [15837728.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6):672-80 [17145347.001]
  • [Cites] Stem Cells Dev. 2007 Jun;16(3):371-80 [17610367.001]
  • [Cites] Bone. 2007 Sep;41(3):346-52 [17618847.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8914-22 [17875734.001]
  • [Cites] J Bone Miner Res. 2007 Dec;22 Suppl 2:V74-80 [18290727.001]
  • [Cites] J Bone Miner Res. 2007 Dec;22 Suppl 2:V86-90 [18290729.001]
  • [Cites] J Bone Miner Res. 2009 Jul;24(7):1263-70 [19257817.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jan;119(1):111-8 [19655244.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Feb;94(1-3):151-7 [15862960.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2563-70 [15687328.001]
  • [Cites] Pharmacol Rev. 2005 Sep;57(3):359-83 [16109840.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7917-25 [16140963.001]
  • [Cites] Eur J Endocrinol. 2005 Dec;153(6):981-8 [16322405.001]
  • [Cites] Toxicology. 2006 Feb 15;219(1-3):33-40 [16330141.001]
  • [Cites] Clin Breast Cancer. 2006 Jun;7(2):127-32 [16800971.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7818-23 [16885386.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2531-42 [16886661.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2551-6 [16886663.001]
  • [Cites] Expert Opin Pharmacother. 2006 Oct;7(14):1919-30 [17020418.001]
  • [Cites] Arch Biochem Biophys. 1999 Nov 15;371(2):179-90 [10545204.001]
  • [Cites] J Cell Biochem. 1999 Dec 15;75(4):640-51 [10572247.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):393-7 [14623536.001]
  • [Cites] Mol Endocrinol. 2004 May;18(5):1109-19 [14963110.001]
  • [Cites] Endocrinology. 2000 Apr;141(4):1317-24 [10746634.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3371-9 [10955825.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2250-5 [11280794.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2328-34 [11280806.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):1043-51 [11309356.001]
  • [Cites] Annu Rev Physiol. 2002;64:93-127 [11826265.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):187-92 [11850224.001]
  • (PMID = 19906814.001).
  • [ISSN] 1945-7170
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA130991; United States / NCI NIH HHS / CA / CA130991
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Prostaglandins; EC 1.14.14.1 / Aromatase; FXC9231JVH / Calcitriol
  • [Other-IDs] NLM/ PMC2803154
  •  go-up   go-down


21. Terrand J, Bruban V, Zhou L, Gong W, El Asmar Z, May P, Zurhove K, Haffner P, Philippe C, Woldt E, Matz RL, Gracia C, Metzger D, Auwerx J, Herz J, Boucher P: LRP1 controls intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt signaling. J Biol Chem; 2009 Jan 2;284(1):381-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LRP1 controls intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt signaling.
  • Here we show that LRP1-deficient fibroblasts accumulate high levels of intracellular cholesterol and cholesteryl-ester when stimulated for adipocyte differentiation.
  • Moreover, we show that LRP1 is required for lipolysis and stimulates fatty acid synthesis independently of the noradrenergic pathway, through inhibition of GSK3beta and its previously unknown target acetyl-CoA carboxylase (ACC).
  • As a result of ACC inhibition, mature LRP1-deficient adipocytes of adult mice are hypotrophic, and lower uptake of fatty acids into adipose tissue leads to their redistribution to the liver.
  • These results establish LRP1 as a novel integrator of adipogenic differentiation and fat storage signals.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 1999 Oct;4(4):611-7 [10549292.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3271-82 [17948131.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):15765-72 [10748179.001]
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1293-307 [10837022.001]
  • [Cites] Science. 2000 Aug 11;289(5481):950-3 [10937998.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):224-8 [11134524.001]
  • [Cites] Science. 2001 Mar 30;291(5513):2613-6 [11283375.001]
  • [Cites] J Clin Invest. 2001 Sep;108(6):779-84 [11560943.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):15507-13 [11854295.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):229-34 [12509515.001]
  • [Cites] Science. 2003 Apr 11;300(5617):329-32 [12690199.001]
  • [Cites] Nature. 2003 May 22;423(6938):448-52 [12717451.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15712-7 [14660788.001]
  • [Cites] Curr Opin Lipidol. 2004 Apr;15(2):175-81 [15017360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4543-7 [15070754.001]
  • [Cites] J Biol Chem. 1980 May 25;255(10):4745-50 [7372608.001]
  • [Cites] J Clin Invest. 1993 Aug;92(2):883-93 [8349823.001]
  • [Cites] Genes Dev. 1994 May 15;8(10):1224-34 [7926726.001]
  • [Cites] J Biol Chem. 1995 Jul 21;270(29):17513-20 [7615556.001]
  • [Cites] Nature. 1996 Jul 18;382(6588):225-30 [8717036.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5336-48 [8895578.001]
  • [Cites] Nat Biotechnol. 1996 Nov;14(11):1562-5 [9634821.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3182-94 [9784493.001]
  • [Cites] Science. 2004 Nov 19;306(5700):1383-6 [15550674.001]
  • [Cites] Cell Metab. 2005 Jan;1(1):15-25 [16054041.001]
  • [Cites] J Thromb Haemost. 2005 Aug;3(8):1884-93 [16102056.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Dec;7(12):885-96 [17139329.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):40236-41 [17074755.001]
  • [Cites] Differentiation. 2007 Mar;75(3):184-92 [17359297.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8433-41 [10567568.001]
  • (PMID = 18990694.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL63762; United States / NHLBI NIH HHS / HL / HL20948; United States / NINDS NIH HHS / NS / NS43408; United States / NIDDK NIH HHS / DK / DK067320; United States / NHLBI NIH HHS / HL / R37 HL063762
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Lrp1 protein, mouse; 0 / Proto-Oncogene Proteins; 0 / Receptors, LDL; 0 / Tumor Suppressor Proteins; 0 / WNT5A protein, human; 0 / Wnt Proteins; 0 / Wnt5a protein, mouse; 97C5T2UQ7J / Cholesterol; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3; EC 6.4.1.2 / Acetyl-CoA Carboxylase
  • [Other-IDs] NLM/ PMC2610522
  •  go-up   go-down


22. Taniguchi T, Usami N, Oohata N, Sakakura N, Souma T, Yokoi K: [Thymolipoma associated with myasthenia gravis]. Kyobu Geka; 2009 Dec;62(13):1154-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A diagnosis of myasthenia gravis was made.
  • Histopathological examination revealed that the tumor consisted of mature adipose tissue and weighed 1,500 grams, in which thymic tissues with Hassall' s corpuscles but without a germinal center were contained.
  • [MeSH-major] Lipoma / complications. Myasthenia Gravis / complications. Thymus Neoplasms / complications

  • Genetic Alliance. consumer health - Myasthenia gravis.
  • MedlinePlus Health Information. consumer health - Myasthenia Gravis.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999094.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 12
  •  go-up   go-down


23. Guallar JP, Cano-Soldado P, Aymerich I, Domingo JC, Alegre M, Domingo P, Villarroya F, Javier Casado F, Giralt M, Pastor-Anglada M: Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients. Antivir Ther; 2007;12(6):853-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients.
  • METHODS: We have examined the expression pattern of NT-encoding genes in human adipose tissue and we have further analysed whether the mRNA related to these genes show changes in their amounts associated with either HIV-1 infection, highly active antiretroviral therapy (HAART) or development of HIV-1-associated lipodystrophy syndrome (HALS).
  • The increase in the mRNA amounts for the former two genes may be due to the action of tumour necrosis factor-alpha (TNF-alpha), a cytokine with enhanced expression in adipose tissue following HIV-1 infection, as the effect is also observed in human adipocytes in culture after treatment with TNF-alpha.
  • CONCLUSIONS: These data suggest that selected genes of the SLC28 and SLC29 families are not only targets of HIV-1 infection, but might also contribute to the development of adipose tissue alterations leading to lipodystrophy.
  • [MeSH-major] Adipose Tissue / metabolism. Equilibrative Nucleoside Transport Proteins / genetics. HIV Infections / metabolism. HIV-1. HIV-Associated Lipodystrophy Syndrome / genetics. Membrane Transport Proteins / genetics
  • [MeSH-minor] Adipocytes / metabolism. Antiretroviral Therapy, Highly Active. Gene Expression Regulation. Humans. RNA, Messenger / genetics. RNA, Messenger / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926640.001).
  • [ISSN] 1359-6535
  • [Journal-full-title] Antiviral therapy
  • [ISO-abbreviation] Antivir. Ther. (Lond.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Equilibrative Nucleoside Transport Proteins; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 0 / cif nucleoside transporter
  •  go-up   go-down


24. Seker M, Bilici A, Sonmez B, Ustaalioğlu BB, Gumus M, Gozu H, Sargin M, Orcun A, Gezen C, Eser M, Bildik N, Salepci T: The association of serum adiponectin levels with histopathological variables in gastric cancer patients. Med Oncol; 2010 Dec;27(4):1319-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adiponectin is a peptide hormone secreted from the adipose tissue, affecting the proliferation and insulin sensitivity in different cell types.
  • We analyzed the correlation among these parameters and patients' demographic features, such as age, gender, body mass index (BMI) and histopathological variables such as tumor localization, stage, nodal status, histological grade, vascular and lymphatic invasion.
  • No relations were detected among tumor stage, tumor localization, nodal status, lymphatic and vascular invasion, and the levels of serum adiponectin (P>0.05).
  • Interestingly, a positive correlation was found between tumor grade and plasma adiponectin levels (r=0.372; P=0.018).
  • But, in undifferentiated tumors, plasma adiponectin level was significantly higher than well-differentiated grade tumors.
  • [MeSH-major] Adiponectin / blood. Stomach / metabolism. Stomach Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Blood Glucose. Body Mass Index. C-Peptide / blood. Case-Control Studies. Female. Gastrectomy. Humans. Insulin / blood. Insulin Resistance. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Obesity. Prognosis. Risk Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):993-7 [12629074.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2764-9 [12050247.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83 [10092513.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):466-72 [15701829.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [16288122.001]
  • [Cites] Nutr Cancer. 2000;38(2):186-91 [11525596.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1595-9 [10845877.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1930-5 [11344187.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5699-704 [14654554.001]
  • [Cites] Eur J Cancer. 2008 Aug;44(12):1744-53 [18515085.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1102-7 [15001594.001]
  • [Cites] J Gastroenterol. 2009;44(7):685-90 [19430715.001]
  • [Cites] Gene. 1997 May 6;190(2):227-35 [9197538.001]
  • [Cites] Diabetes. 2002 Oct;51(10):2964-7 [12351434.001]
  • [Cites] Lancet. 2002 Jul 6;360(9326):57-8 [12114044.001]
  • [Cites] Horm Metab Res. 2002 Sep;34(9):469-74 [12384822.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1160-3 [15001602.001]
  • [Cites] Diabetes Metab. 2004 Feb;30(1):13-9 [15029093.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):337-40 [10365891.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):749-56 [9752982.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):421-30 [11169969.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1120-7 [17459059.001]
  • (PMID = 20013320.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Blood Glucose; 0 / C-Peptide; 0 / Insulin
  •  go-up   go-down


25. Pierron A, Fernandez C, Saada E, Keslair F, Hery G, Zattara H, Pedeutour F: HMGA2-NFIB fusion in a pediatric intramuscular lipoma: a novel case of NFIB alteration in a large deep-seated adipocytic tumor. Cancer Genet Cytogenet; 2009 Nov;195(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HMGA2-NFIB fusion in a pediatric intramuscular lipoma: a novel case of NFIB alteration in a large deep-seated adipocytic tumor.
  • We found a translocation t(9;12)(p22;q14) in a deep-seated intramuscular lipoma occurring in the buttock of a 5-year-old boy.
  • Both the truncation of HMGA2 and the nature of its fusion partner gene might be relevant in the adipose tissue tumorigenesis.
  • [MeSH-major] Adipose Tissue / metabolism. HMGA2 Protein / genetics. Lipoma / genetics. NFI Transcription Factors / genetics. Oncogene Proteins, Fusion / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19837271.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein; 0 / NFI Transcription Factors; 0 / NFIB protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


26. Beasley LE, Koster A, Newman AB, Javaid MK, Ferrucci L, Kritchevsky SB, Kuller LH, Pahor M, Schaap LA, Visser M, Rubin SM, Goodpaster BH, Harris TB, Health ABC study: Inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity (Silver Spring); 2009 May;17(5):1062-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammation and race and gender differences in computerized tomography-measured adipose depots.
  • It is unclear whether the size of specific adipose depots is more closely associated with concentrations of inflammatory markers than overall adiposity.
  • Inflammatory markers, interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-alpha) were obtained from serum samples.
  • Linear regression analysis was used to evaluate the cross-sectional relationship between specific adipose depots and inflammatory markers in four race/gender groups.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Epidemiol. 1997 Apr;50(4):377-83 [9179095.001]
  • [Cites] Circulation. 1997 Feb 18;95(4):778-81 [9054727.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4196-200 [9398739.001]
  • [Cites] Am J Clin Nutr. 1999 Mar;69(3):381-7 [10075320.001]
  • [Cites] Eur J Clin Invest. 1999 Aug;29(8):672-8 [10457150.001]
  • [Cites] Diabetologia. 2005 Feb;48(2):301-8 [15660262.001]
  • [Cites] Am J Cardiol. 2005 Jul 1;96(1):92-7 [15979442.001]
  • [Cites] J Endocrinol. 2006 Dec;191(3):699-706 [17170226.001]
  • [Cites] Diabetes. 2007 Apr;56(4):1010-3 [17287468.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2007 May;17(4):294-302 [17434052.001]
  • [Cites] J Investig Med. 2007 Jan;55(1):26-35 [17441409.001]
  • [Cites] Horm Metab Res. 2007 Jul;39(7):515-8 [17611905.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):881-3 [11397691.001]
  • [Cites] Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504 [10993420.001]
  • [Cites] Circulation. 2007 Sep 11;116(11):1234-41 [17709633.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):961-7 [11397704.001]
  • [Cites] Obes Res. 2001 Jul;9(7):381-7 [11445659.001]
  • [Cites] Int J Obes Relat Metab Disord. 2001 Sep;25(9):1327-31 [11571595.001]
  • [Cites] Circulation. 2002 Feb 19;105(7):804-9 [11854119.001]
  • [Cites] Diabetes. 2002 Oct;51(10):2951-8 [12351432.001]
  • [Cites] J Am Geriatr Soc. 2004 Mar;52(3):399-404 [14962155.001]
  • [Cites] Diabetes Care. 2004 Jun;27(6):1375-80 [15161791.001]
  • [Cites] Diabetes Obes Metab. 2004 Jul;6(4):249-58 [15171748.001]
  • [Cites] Int J Obes Relat Metab Disord. 2004 Jul;28(7):925-32 [15148505.001]
  • [Cites] Circulation. 2004 Jul 27;110(4):380-5 [15262834.001]
  • [Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]
  • [Cites] Eur J Epidemiol. 1994 Aug;10(4):405-11 [7843344.001]
  • [Cites] Psychol Med. 1997 Jan;27(1):231-5 [9122304.001]
  • [Cites] Diabetes. 1997 Oct;46(10):1579-85 [9313753.001]
  • (PMID = 19165157.001).
  • [ISSN] 1930-7381
  • [Journal-full-title] Obesity (Silver Spring, Md.)
  • [ISO-abbreviation] Obesity (Silver Spring)
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / N01-AG-6-2101; United States / NIA NIH HHS / AG / N01 AG062101; United States / NIA NIH HHS / AG / N01-AG-6-2103; United States / NIA NIH HHS / AG / N01 AG062106; United States / Intramural NIH HHS / / ; United States / NIA NIH HHS / AG / N01 AG062103; United States / NIA NIH HHS / AG / N01-AG-6-2106; United States / NIA NIH HHS / AG / P30 AG021332
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ NIHMS106432; NLM/ PMC3268118
  •  go-up   go-down


27. Dauplat MM, Penault-Llorca F: [Diagnostic pitfalls in mammary pathology. Case 8. Breast metastases of a malignant melanoma]. Ann Pathol; 2009 Jun;29(3):228-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic pitfalls in mammary pathology. Case 8. Breast metastases of a malignant melanoma].
  • [MeSH-major] Breast Neoplasms / secondary. Melanoma / secondary
  • [MeSH-minor] Adipose Tissue / pathology. Age Factors. Aged. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma, Ductal, Breast / therapy. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. MART-1 Antigen. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619831.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


28. Tchkonia T, Tchoukalova YD, Giorgadze N, Pirtskhalava T, Karagiannides I, Forse RA, Koo A, Stevenson M, Chinnappan D, Cartwright A, Jensen MD, Kirkland JL: Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. Am J Physiol Endocrinol Metab; 2005 Jan;288(1):E267-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In studies of colonies arising from single preadipocytes, two preadipocyte subtypes were found, one capable of more extensive replication, differentiation, and adipogenic transcription factor expression and less apoptosis in response to TNF-alpha than the other.
  • The former was more abundant in subcutaneous and mesenteric than in omental preadipocyte populations, potentially contributing to regional variation in replication, differentiation, and apoptosis.
  • Thus proportions of preadipocyte subtypes with distinct cell-dynamic properties vary among depots, potentially permitting tissue plasticity through subtype selection during development.
  • Furthermore, mesenteric preadipocyte cell-dynamic characteristics are distinct from omental cells, indicating that visceral fat depots are not functionally uniform.
  • [MeSH-major] Adipocytes / cytology. Adipose Tissue / cytology. Stem Cells / cytology
  • [MeSH-minor] Adult. Apoptosis / drug effects. Apoptosis / physiology. CCAAT-Enhancer-Binding Protein-alpha / metabolism. Cell Communication / physiology. Cell Division / physiology. Cells, Cultured. Female. Humans. Male. Middle Aged. Tumor Necrosis Factor-alpha / pharmacology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15383371.001).
  • [ISSN] 0193-1849
  • [Journal-full-title] American journal of physiology. Endocrinology and metabolism
  • [ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG-13925; United States / NIA NIH HHS / AG / AG-23960; United States / NIDDK NIH HHS / DK / DK-45343; United States / NIDDK NIH HHS / DK / DK-46200; United States / NIDDK NIH HHS / DK / DK-56891
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


29. German AJ, Hervera M, Hunter L, Holden SL, Morris PJ, Biourge V, Trayhurn P: Improvement in insulin resistance and reduction in plasma inflammatory adipokines after weight loss in obese dogs. Domest Anim Endocrinol; 2009 Nov;37(4):214-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Obesity is now a major disease of dogs, predisposing to numerous disorders including diabetes mellitus.
  • Weight loss also led to notable decreases in plasma tumor necrosis factor-alpha (TNF-alpha), haptoglobin, and C-reactive protein concentrations (P<0.05 for all), suggesting improvement of a subclinical inflammatory state associated with obesity.
  • Concurrent decreases in TNF-alpha and adipose tissue mass suggest that in dogs, as in humans, this adipokine may be implicated in the insulin resistance of obesity.

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Weight Control.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19674864.001).
  • [ISSN] 1879-0054
  • [Journal-full-title] Domestic animal endocrinology
  • [ISO-abbreviation] Domest. Anim. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Adipokines; 0 / Blood Glucose; 0 / Chemokines; 0 / Cytokines; 0 / Insulin
  •  go-up   go-down


30. Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, Yki-Jărvinen H, Back DJ, Pirmohamed M, Gazzard BG, Walker UA, Moyle GJ: Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr; 2005 Dec 15;40(5):565-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the relations between mitochondrial toxicity, adipokine expression, and clinical LA in peripheral blood mononuclear cells (PBMCs) and adipose samples from individuals treated with stavudine (d4T) or zidovudine (ZDV) in comparison to patients undergoing highly active antiretroviral therapy (HAART) as well as HIV-negative individuals.
  • Adipose samples were assessed for protein and/or messenger RNA (mRNA) levels of adiponectin, tumor necrosis factor-alpha (TNFalpha), interleukin (IL)-6, and sterol regulatory element-binding protein (SREBP) 1a/c in all groups, whereas adipose and PBMC samples from the d4T+LA+, ZDV+LA+, and HIV-negative subgroups were assessed for mitochondrial DNA (mtDNA) depletion and cytochrome c-oxidase (COX) II/COX IV ratios.
  • RESULTS: There was no change in mtDNA levels in adipose or PBMC samples in NRTI-treated patients with LA, although patients treated with d4T had reduced COX II/COX IV ratios in adipose and PBMC samples.
  • Adipose tissue adiponectin mRNA and plasma levels were reduced in the d4T- and ZDV-treated patients regardless of the use of PIs.
  • Tissue SREBP1c mRNA levels were also significantly reduced in both NRTI groups when compared with the HIV-negative controls.
  • [MeSH-major] Adipose Tissue / metabolism. Anti-HIV Agents / adverse effects. HIV Infections / drug therapy. HIV-Associated Lipodystrophy Syndrome / drug therapy. Mitochondria / drug effects. Reverse Transcriptase Inhibitors / adverse effects. Stavudine / adverse effects. Zidovudine / adverse effects
  • [MeSH-minor] Adiponectin / metabolism. Adult. Antiretroviral Therapy, Highly Active. DNA, Mitochondrial / blood. Drug Therapy, Combination. HIV-1 / drug effects. Humans. Interleukin-6 / metabolism. Male. Middle Aged. Sterol Regulatory Element Binding Protein 1 / metabolism. Tumor Necrosis Factor-alpha / metabolism


31. Lee SA, Kallianpur A, Xiang YB, Wen W, Cai Q, Liu D, Fazio S, Linton MF, Zheng W, Shu XO: Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. Cancer Epidemiol Biomarkers Prev; 2007 Nov;16(11):2464-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adipokines, soluble mediators produced by adipocytes, may link adipose tissue to the inflammatory, metabolic, and immune dysregulation that characterize many obesity-related diseases.
  • We measured levels of 12 adipokines [interleukin 1beta (IL-1beta), IL-6, IL-8, tumor necrosis factor-alpha (TNF-alpha), plasminogen activator inhibitor-1 (PAI-1), high-sensitivity C-reactive protein (hsCRP), monocyte chemoattractant protein-1 (MCP-1), nerve growth factor (NGF), leptin, adiponectin, hepatocyte growth factor (HGF), and resistin] in four seasonal random plasma samples of 48 male participants of a population-based cohort study.
  • The representativeness of single measurements was assessed by correlating the adipokine levels of a single, random sample with the mean levels from the remaining three samples using a bootstrap approach and using intra-class correlation coefficients (ICC).
  • This study suggests that adipokine levels in a single blood sample may be useful biomarkers of inflammation in population-based studies of obesity-related disease.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006938.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082729; United States / NCI NIH HHS / CA / R01CA82729
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines
  •  go-up   go-down


32. McHugh JB, Fullen DR: Atypical compound nevus arising in mature cystic ovarian teratoma. Med Sci Monit; 2006 Apr;12(4):CS34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Mature cystic ovarian teratoma (MCOT) is the most common primary ovarian tumor.
  • Histologically, the cystic neoplasm demonstrated epidermis with numerous pilosebaceous units and respiratory-type epithelium (endoderm) surrounded by adipose tissue and cartilage (mesoderm).
  • Diagnostic criteria of melanoma were not identified.
  • No features of melanoma were present and the patient is disease-free at one-year follow-up.
  • Moreover, melanomas may arise de novo or in association with a nevus.
  • As primary ovarian melanomas, like their skin counterpart, may arise from a precursor lesion, removal of a melanocytic nevus, such as this atypical nevus, could theoretically prevent melanoma transformation.
  • [MeSH-major] Neoplasms, Multiple Primary / diagnosis. Nevus, Pigmented / diagnosis. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16572057.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


33. Genevay S, Finckh A, Payer M, Mezin F, Tessitore E, Gabay C, Guerne PA: Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc. Spine (Phila Pa 1976); 2008 Sep 1;33(19):2041-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc.
  • OBJECTIVE: To determine whether inflammatory cytokines [tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and IL-8] are elevated in tissues intimately surrounding involved nerve roots of patients suffering from radiculopathy form herniated disc (HD).
  • Although TNF-alpha has been found in human HD, it is not known whether TNF-alpha concentrations are increased in symptomatic patients.
  • Epidural fat (EF) is another tissue in close contact with nerve roots.
  • Tissue explants were incubated ex vivo for 48 hours and the concentrations of cytokines were measured by elisa in the supernatants.
  • Results were standardized according to tissue weight.
  • TNF-alpha was the only cytokine found in significantly higher levels in EFHD compared with EFC [median, interquartile range 6.6, (1.6-16.3) pg/mL per milligram of tissue vs. 2.3 (1.3-5.0), P < 0.05] and to subcutaneous fat [0.35 (0-2.28), P < 0.001].
  • [MeSH-major] Adipose Tissue / metabolism. Intervertebral Disc Displacement / metabolism. Radiculopathy / metabolism. Spinal Nerve Roots / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Herniated Disk.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758358.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


34. Duvnjak L, Duvnjak M: The metabolic syndrome - an ongoing story. J Physiol Pharmacol; 2009 Dec;60 Suppl 7:19-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metabolic abnormalities result from the interaction between the effects of insulin resistance located primarily in the muscle and adipose tissue and the adverse impact of the compensatory hyperinsulinaemia on tissues that remain normally insulin-sensitive.
  • The clinical heterogeneity of the syndrome can be explained by its significant impact on glucose, fat and protein metabolism, cellular growth and differentiation, and endothelial function.
  • Moderating the secretion of adipocytokines like leptin, adiponectin, plasminogen activator inhibitor 1 (PAI-1), tumor necrosis factor alfa (TNF-alfa), interleukin-6 (IL-6) and resistin, it is associated with the processes of inflammation, endothelial dysfunction, hypertension and atherogenesis.
  • Visceral obesity measured by waist circumference is an essential requirement for diagnosis; other variables include increased triglyceride and decreased HDL levels, hypertension and glucose impairment.
  • Whatever the uncertainties of definition and etiology, metabolic syndrome represents a useful and simple clinical concept which allows earlier detection of type 2 diabetes and cardiovascular disease.
  • [MeSH-minor] Abdominal Fat / metabolism. Abdominal Fat / secretion. Adiposity. Animals. Cardiovascular Diseases / prevention & control. Diabetes Mellitus, Type 2 / prevention & control. Early Diagnosis. Humans. Insulin Resistance. Risk Factors. Terminology as Topic

  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388942.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 46
  •  go-up   go-down


35. Pantsulaia I, Livshits G, Trofimov S, Kobyliansky E: Genetic and environmental determinants of circulating resistin level in a community-based sample. Eur J Endocrinol; 2007 Jan;156(1):129-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Resistin is a hormone secreted by adipose tissue, monocytes, bone marrow, and other tissues.
  • The main objective of this study was to elucidate the contribution of a number of endogenous factors, such as sex, age, obesity characteristics, and genetic effects to the production of resistin in apparently healthy individuals.
  • We also tested the possible relationships between circulating levels of resistin and other adipokines (leptin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)).

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17218736.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0 / Interleukin-6; 0 / Leptin; 0 / Resistin; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


36. Guerrero J, Tobar N, Cáceres M, Espinoza L, Escobar P, Dotor J, Smith PC, Martínez J: Soluble factors derived from tumor mammary cell lines induce a stromal mammary adipose reversion in human and mice adipose cells. Possible role of TGF-beta1 and TNF-alpha. Breast Cancer Res Treat; 2010 Jan;119(2):497-508
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble factors derived from tumor mammary cell lines induce a stromal mammary adipose reversion in human and mice adipose cells. Possible role of TGF-beta1 and TNF-alpha.
  • In the case of breast tissue, in which stroma is mainly a fatty tissue, this response presumably occurs at the expense of the adipose cells, the most abundant stromal phenotype, generating a tumoral fibrous structure rich in fibroblast-like cells.
  • In this study, we aimed to determine the cellular mechanisms by which factors present in the media conditioned by MDA-MB-231 and MCF-7 human breast cancer cell lines induce a reversion of adipose cells to a fibroblastic phenotype.
  • We demonstrated that soluble factors generated by these cell lines stimulated the reversion of mammary adipose phenotype evaluated as intracellular lipid content and expression of C/EBP alpha and PPAR gamma.
  • [MeSH-major] Adipocytes / metabolism. Breast Neoplasms / metabolism. Cell Transdifferentiation. Fibroblasts / metabolism. Transforming Growth Factor beta1 / metabolism. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] 3T3-L1 Cells. Animals. Blotting, Western. CCAAT-Enhancer-Binding Proteins / metabolism. Cell Line, Tumor. Cell Size. Culture Media, Conditioned / metabolism. Female. Humans. Immunohistochemistry. Mice. PPAR gamma / metabolism. Phenotype. Recombinant Proteins / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19649705.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / CEBPA protein, mouse; 0 / Culture Media, Conditioned; 0 / PPAR gamma; 0 / Recombinant Proteins; 0 / Transforming Growth Factor beta1; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


37. Fan X, Abe H, Medved M, Foxley S, Arkani S, Zamora MA, Olopade OI, Newstead GM, Karczmar GS: Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. J Magn Reson Imaging; 2006 Dec;24(6):1311-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Fat suppression, tumor edge delineation, lesion conspicuity, and image texture were improved in the peak height images derived from HiSS data.
  • CONCLUSION: The results demonstrate that the water peak height images obtained from HiSS data potentially could improve the quality of fat suppression, detection and diagnosis of breast cancer.
  • [MeSH-major] Adipose Tissue / pathology. Breast / pathology. Breast Neoplasms / pathology. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Subtraction Technique

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096393.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB003108-01; United States / NCI NIH HHS / CA / R01CA78803
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


38. Fernandez MF, Santa-Marina L, Ibarluzea JM, Exposito J, Aurrekoetxea JJ, Torne P, Laguna J, Rueda AI, Pedraza V, Olea N: Analysis of population characteristics related to the total effective xenoestrogen burden: a biomarker of xenoestrogen exposure in breast cancer. Eur J Cancer; 2007 May;43(8):1290-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To analyse the link between breast cancer and the combined effect of environmental xenoestrogens, we developed, standardised and applied a biomarker of exposure to assess the total effective xenoestrogen burden (TEXB) in human adipose tissue in a case-control study.
  • In conclusion, TEXB, as a biomarker of exposure, takes account of environmental, dietary, lifestyle, genetic and reproductive factors, which are not usually systematically measured across studies.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Environmental Exposure / adverse effects. Estrogens / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466515.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogens
  •  go-up   go-down


39. Chen H, Vlahos R, Bozinovski S, Jones J, Anderson GP, Morris MJ: Effect of short-term cigarette smoke exposure on body weight, appetite and brain neuropeptide Y in mice. Neuropsychopharmacology; 2005 Apr;30(4):713-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, we aimed to investigate how cigarette smoking affects body weight, food intake, plasma leptin concentration, hypothalamic NPY peptide, adipose mass and mRNA expression of uncoupling proteins (UCP), and tumor necrosis factor (TNF) alpha.
  • [MeSH-minor] Adipose Tissue / drug effects. Adipose Tissue / metabolism. Animals. Carrier Proteins / genetics. Disease Models, Animal. Down-Regulation / drug effects. Down-Regulation / physiology. Drug Administration Schedule. Energy Metabolism / drug effects. Energy Metabolism / physiology. Hypothalamus / drug effects. Hypothalamus / metabolism. Hypothalamus / physiopathology. Ion Channels. Leptin / blood. Male. Membrane Proteins / genetics. Mice. Mice, Inbred BALB C. Mitochondrial Proteins. RNA, Messenger / drug effects. RNA, Messenger / metabolism. Time Factors. Tobacco Use Disorder / metabolism. Tobacco Use Disorder / physiopathology. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Body Weight.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15508020.001).
  • [ISSN] 0893-133X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Ion Channels; 0 / Leptin; 0 / Membrane Proteins; 0 / Mitochondrial Proteins; 0 / Neuropeptide Y; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 0 / mitochondrial uncoupling protein; 0 / mitochondrial uncoupling protein 3; 6M3C89ZY6R / Nicotine
  •  go-up   go-down


40. Bassett MD, Schuetze SM, Disteche C, Norwood TH, Swisshelm K, Chen X, Bruckner J, Conrad EU 3rd, Rubin BP: Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognostication. Cancer; 2005 Jan 15;103(2):409-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognostication.
  • BACKGROUND: Intramuscular lipomas and atypical lipomatous tumors (ALT) are common deep-seated lipomatous tumors of the chest wall and extremities.
  • Correct classification is important, because aggressive local disease recurrence occurs more frequently in patients with ALT than in patients with intramuscular lipoma.
  • METHODS: In the current study, 106 patients with deep-seated, well differentiated adipose tumors of the chest wall and extremities were classified as having ALT or intramuscular lipoma using a combined approach of histology and cytogenetics, if available.
  • Classification did not correlate with age and gender (P = 0.28 and P = 0.96, respectively).
  • Four percent of patients with intramuscular lipomas and 27% of patients with ALTs developed local disease recurrence (P = 0.0006).
  • Disease recurrence did not correlate with patient age at diagnosis, patient gender, tumor size, and tumor location (P = 0.45, P = 0.26, P = 0.49, and P = 0.28, respectively).
  • Within the subset of patients with ALTs, disease recurrence did not correlate with patient age at diagnosis, patient gender, or tumor location (P = 0.38, P = 0.54, and P = 0.86, respectively).
  • CONCLUSIONS: Classification of deep-seated, well differentiated lipomatous tumors of the extremities and chest wall using a combined approach of histology and cytogenetics correlated well with biologic behavior/disease recurrence.
  • [MeSH-major] Liposarcoma / genetics. Liposarcoma / pathology. Neoplasm Recurrence, Local / pathology. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / pathology. Thoracic Wall / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cohort Studies. Cytogenetics. Female. Humans. Immunohistochemistry. Incidence. Lower Extremity. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Registries. Sensitivity and Specificity. Sex Distribution. Upper Extremity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15593324.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Jenkins P, Anjarwalla S, Gilbert H, Kinder R: Defining the clinical target volume for bladder cancer radiotherapy treatment planning. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1379-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: There are currently no data for the expansion margin required to define the clinical target volume (CTV) around bladder tumors.
  • This information is particularly relevant when perivesical soft tissue changes are seen on the planning scan.
  • The presence and extent of tumor growth beyond the outer bladder wall was measured radiologically and histopathologically.
  • RESULTS: Forty one (51%) patients had histologically confirmed tumor extension into perivesical fat.
  • False-positive results were infrequent and not affected by either the timing or the amount of tissue resected at TUR.
  • Tumor size and the presence of either lymphovascular invasion or squamoid differentiation predict a greater extent of EVE.
  • CONCLUSIONS: In patients with radiological evidence of extravesical disease, the CTV should comprise the outer bladder wall plus a 10-mm margin.
  • In patients with no evidence of extravesical disease on CT scans, the CTV should be restricted to the outer bladder wall plus a 6-mm margin.
  • These recommendations would encompass microscopic disease extension in 90% of cases.
  • [MeSH-major] Radiotherapy Planning, Computer-Assisted / methods. Tumor Burden. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Adipose Tissue / pathology. Adipose Tissue / radiography. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiography. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Cystectomy. False Positive Reactions. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Radiotherapy Dosage. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394154.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Lappalainen T, Kolehmainen M, Schwab U, Pulkkinen L, de Mello VD, Vaittinen M, Laaksonen DE, Poutanen K, Uusitupa M, Gylling H: Gene expression of FTO in human subcutaneous adipose tissue, peripheral blood mononuclear cells and adipocyte cell line. J Nutrigenet Nutrigenomics; 2010;3(1):37-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression of FTO in human subcutaneous adipose tissue, peripheral blood mononuclear cells and adipocyte cell line.
  • We compared the FTO gene expression in subcutaneous adipose tissue and peripheral blood mononuclear cells (PBMCs) between overweight and normal weight individuals.
  • We also investigated if mRNA levels of FTO in adipose tissue correlated with the adiposity or inflammatory markers and mRNA levels of genes involved in the response to hypoxia (HIF-1a) and cell death(HMGB1).
  • RESULTS: The mRNA expression of FTO in adipose tissue was greater in obese than normal weight individuals (p < 0.001), but there was no difference in FTO expression in PBMCs.
  • FTO mRNA levels did not correlate with adiposity or inflammatory markers and FTO expression was not influenced by the FTO rs9939609 genotype.
  • FTO mRNA level correlated positively with gene expression levels of HIF-1a and HMGB1 in subcutaneous adipose tissue (r = 0.59, p < 0.001; r = 0.69, p < 0.001, respectively; adjusted for BMI and adipocyte cell size).
  • CONCLUSIONS: Altogether, FTO expression appeared not to have a well-defined impact on clinical or biochemical parameters comprising the metabolic syndrome.
  • [MeSH-minor] Blood Glucose / metabolism. Body Mass Index. C-Reactive Protein / metabolism. Female. Genotype. Humans. Interleukin-6 / blood. Male. Middle Aged. Obesity / blood. Obesity / genetics. Obesity / metabolism. Polymerase Chain Reaction / methods. RNA / genetics. RNA / isolation & purification. Reference Values. Tumor Necrosis Factor-alpha / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20948226.001).
  • [ISSN] 1661-6499
  • [Journal-full-title] Journal of nutrigenetics and nutrigenomics
  • [ISO-abbreviation] J Nutrigenet Nutrigenomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / FTO protein, human; 0 / Interleukin-6; 0 / Proteins; 0 / Tumor Necrosis Factor-alpha; 63231-63-0 / RNA; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


43. Bulun SE, Simpson ER: Aromatase expression in women's cancers. Adv Exp Med Biol; 2008;630:112-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovary, testis, adipose tissue, skin, hypothalamus and placenta express aromatase normally, whereas breast, endometrial and ovarian cancers overexpress aromatase and produce local estrogen exerting paracrine and intracrine effects.
  • Tissue specific promoters distributed over a 93 kilobase regulatory region upstream of a common coding region alternatively control aromatase expression.
  • A distinct set of transcription factors regulates each promoter in a signaling pathway- and tissue-specific manner.
  • In breast adipose fibroblasts exposed to PGE2 secreted by malignant epithelial cells, activation of PKC potentiates cAMP-PKA-dependent induction ofaromatase.
  • Thus, inflammatory substances such as PGE2 may play important roles in inducing local production of estrogen that promotes tumor growth.
  • [MeSH-major] Aromatase / genetics. Gene Expression. Neoplasms / genetics
  • [MeSH-minor] Adipose Tissue / physiology. Aromatase Inhibitors / therapeutic use. Endometriosis / complications. Female. Gene Expression Regulation, Neoplastic / drug effects. Hormones / pharmacology. Humans. Models, Biological

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637488.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA67167; United States / NICHD NIH HHS / HD / HD38691; United States / NICHD NIH HHS / HD / HD46260
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Hormones; EC 1.14.14.1 / Aromatase
  • [Number-of-references] 119
  •  go-up   go-down


44. Dickson ME, Tian X, Liu X, Davis DR, Sigmund CD: Upstream stimulatory factor is required for human angiotensinogen expression and differential regulation by the A-20C polymorphism. Circ Res; 2008 Oct 24;103(9):940-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upstream stimulatory factor is required for human angiotensinogen expression and differential regulation by the A-20C polymorphism.
  • We show herein that the -20C allele has higher transcriptional activity than -20A, and the -20A allele confers no additional transactivation potential beyond that of a mutated vector.
  • Chromatin immunoprecipitation confirmed that USF1 binds to the endogenous AGT -20C allele in CCF cells, the only cell line tested that carries the -20C allele, and to the human AGT promoter in liver and adipose tissue from transgenic mice.
  • [MeSH-minor] 3T3-L1 Cells. Adipose Tissue / metabolism. Animals. Cell Line, Tumor. Chromatin Immunoprecipitation. Electrophoretic Mobility Shift Assay. Humans. Liver / metabolism. Mice. Mice, Transgenic. RNA Interference. RNA, Small Interfering / metabolism. Transfection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Physiol Genomics. 1999 Jul 15;1(1):3-9 [11015555.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):108-23 [11731937.001]
  • [Cites] J Hum Genet. 2002;47(1):7-13 [11829142.001]
  • [Cites] Hypertension. 2002 Feb;39(2 Pt 2):629-33 [11882621.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33235-41 [12080069.001]
  • [Cites] Int J Mol Med. 2003 Aug;12(2):161-7 [12851711.001]
  • [Cites] Circulation. 2003 Aug 5;108(5):519-23 [12847072.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):7770-6 [14672953.001]
  • [Cites] Cell. 1992 Oct 2;71(1):169-80 [1394429.001]
  • [Cites] J Biol Chem. 1994 Dec 23;269(51):32497-502 [7798251.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2735-9 [7708716.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1405-15 [8576131.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1786-97 [9120024.001]
  • [Cites] Hypertension. 1997 Dec;30(6):1325-30 [9403548.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3758-63 [9520440.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):20175-9 [9685363.001]
  • [Cites] Hypertension. 1999 Jan;33(1):108-15 [9931090.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21285-90 [10409686.001]
  • [Cites] Mol Cell. 2004 Nov 5;16(3):453-63 [15525517.001]
  • [Cites] J Mol Med (Berl). 2005 Feb;83(2):121-31 [15630592.001]
  • [Cites] BMC Bioinformatics. 2005;6:79 [15799782.001]
  • [Cites] Diabetes. 2005 Jul;54(7):1976-84 [15983197.001]
  • [Cites] Methods Mol Biol. 2005;309:219-35 [15990403.001]
  • [Cites] Hum Mol Genet. 2005 Sep 1;14(17):2595-605 [16076849.001]
  • [Cites] Hum Genet. 2005 Sep;117(5):444-51 [15959806.001]
  • [Cites] Diabetologia. 2005 Oct;48(10):2018-24 [16132950.001]
  • [Cites] Hypertension. 2006 Jul;48(1):14-20 [16754793.001]
  • [Cites] Hypertension. 2007 Mar;49(3):631-9 [17200439.001]
  • [Cites] J Biol Chem. 2007 Feb 23;282(8):5453-67 [17197698.001]
  • [Cites] Science. 2007 Jul 6;317(5834):118-21 [17525304.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(22):7991-8002 [17846119.001]
  • [Cites] Physiol Genomics. 2007 Nov 14;31(3):554-62 [17804605.001]
  • (PMID = 18802024.001).
  • [ISSN] 1524-4571
  • [Journal-full-title] Circulation research
  • [ISO-abbreviation] Circ. Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R37 HL048058-13; United States / NHLBI NIH HHS / HL / R01 HL061446-07; United States / NHLBI NIH HHS / HL / R37 HL048058; United States / NHLBI NIH HHS / HL / P01 HL084207-01A1; United States / NHLBI NIH HHS / HL / R37 HL048058-14; United States / NHLBI NIH HHS / HL / R01 HL061446; United States / NHLBI NIH HHS / HL / R01 HL061446-06; United States / NHLBI NIH HHS / HL / P01 HL084207-020001; United States / NHLBI NIH HHS / HL / HL84207; United States / NHLBI NIH HHS / HL / P01 HL084207; United States / NHLBI NIH HHS / HL / P01 HL084207-02; United States / NHLBI NIH HHS / HL / HL48058; United States / NHLBI NIH HHS / HL / R01 HL061446-10; United States / NHLBI NIH HHS / HL / R01 HL061446-08; United States / NHLBI NIH HHS / HL / R01 HL061446-09; United States / NHLBI NIH HHS / HL / R01 HL048058; United States / NHLBI NIH HHS / HL / HL61446
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / USF1 protein, human; 0 / USF2 protein, human; 0 / Upstream Stimulatory Factors; 0 / Usf1 protein, mouse; 0 / Usf2 protein, mouse; 11002-13-4 / Angiotensinogen
  • [Other-IDs] NLM/ NIHMS69595; NLM/ PMC2678906
  •  go-up   go-down


45. Nicola M, Gulfi G, Milanesi S, De Luca F: Spontaneous rupture of renal angiomyolipoma in pregnancy at 15 weeks gestation. Arch Ital Urol Androl; 2007 Dec;79(4):179-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal angiomyolipoma (AML) is a rare bening tumor of kidney origin.
  • It is majority comprised adipose tissue, blood vesses and smooth muscle.
  • We report a case of a spontaneous rupture of renal angiomyolipoma in a 37-year-old pregnant woman.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303739.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


46. Harte A, McTernan P, Chetty R, Coppack S, Katz J, Smith S, Kumar S: Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation; 2005 Apr 19;111(15):1954-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Identification of the renin-angiotensin system (RAS) within adipose tissue does, however, suggest a potential causal role for it in obesity-associated hypertension.
  • Obese patients are often hyperinsulinemic, but mechanisms underlying insulin upregulation of the RAS in adipose tissue are unclear.
  • Tumor necrosis factor-alpha (TNF-alpha), an inducer of angiotensinogen in hepatocytes, is elevated in hyperinsulinemic, obese individuals and may provide a link in mediating insulin upregulation of the RAS in adipose tissue.
  • Furthermore, thiazolidinediones lower blood pressure in vivo, and downregulation of the RAS in adipose tissue may contribute to this effect.
  • METHODS AND RESULTS: Sera were obtained from the arterial circulation and from venous blood by draining subcutaneous abdominal adipose tissue.
  • CONCLUSIONS: The present in vivo data suggest that human subcutaneous adipose tissue is a significant source of angiotensin II.
  • RSG downregulates the RAS in subcutaneous adipose tissue, and this effect may contribute to the long-term effect of RSG on blood pressure.
  • [MeSH-minor] Angiotensin II / secretion. Antihypertensive Agents / pharmacology. Cells, Cultured. Drug Antagonism. Humans. Obesity / complications. Tumor Necrosis Factor-alpha / pharmacology. Tumor Necrosis Factor-alpha / secretion

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837949.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Insulin; 0 / Thiazolidinediones; 0 / Tumor Necrosis Factor-alpha; 05V02F2KDG / rosiglitazone; 11128-99-7 / Angiotensin II
  •  go-up   go-down


47. Amin SA, Huang CC, Reierstad S, Lin Z, Arbieva Z, Wiley E, Saborian H, Haynes B, Cotterill H, Dowsett M, Bulun SE: Paracrine-stimulated gene expression profile favors estradiol production in breast tumors. Mol Cell Endocrinol; 2006 Jul 11;253(1-2):44-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
  • Paracrine interactions between adipose fibroblasts and malignant epithelial cells are essential for structural and hormonal support of breast tumors.
  • Factors derived from malignant epithelial cells inhibit adipogenic differentiation of fibroblasts and upregulate expression of aromatase, which stimulates estrogen synthesis and creates a localized, growth-stimulatory environment.
  • Here, we characterized the gene expression profile of breast adipose fibroblasts in an in vitro model of malignancy to identify other paracrine interactions that support tumor growth.
  • Primary breast adipose fibroblasts from cancer-free women were treated with conditioned media from malignant breast epithelial cells or normal breast epithelial cells, and differences in gene expression were identified by microarray.
  • Importantly, AKR1C3 and aromatase mRNA levels correlated positively in 61 malignant breast tumors (R=0.3967, p=0.00156).
  • Malignant epithelial cell-conditioned medium significantly increased formation of testosterone and estradiol from androstenedione in breast adipose fibroblasts.
  • In conclusion, malignant epithelial cell-derived factors significantly upregulate the enzymes AKR1C3 and aromatase that catalyze a series of complementary reactions to convert the circulating precursor androstenedione to biologically active estradiol in vitro in the stromal fibroblasts, and in vivo, in stromal component of breast tumors.
  • [MeSH-major] Breast Neoplasms / metabolism. Estradiol / metabolism. Fibroblasts / metabolism. Gene Expression Profiling. Paracrine Communication / genetics
  • [MeSH-minor] 3-Hydroxysteroid Dehydrogenases / genetics. 3-Hydroxysteroid Dehydrogenases / metabolism. Adipose Tissue / cytology. Adolescent. Adult. Aromatase / genetics. Aromatase / metabolism. Cell Line, Tumor. Cells, Cultured. Culture Media, Conditioned / pharmacology. Female. Humans. Hydroxyprostaglandin Dehydrogenases / genetics. Hydroxyprostaglandin Dehydrogenases / metabolism. Immunohistochemistry. Middle Aged. Polymerase Chain Reaction. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735089.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA67167
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / RNA, Messenger; 4TI98Z838E / Estradiol; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; EC 1.1.1.- / AKR1C3 protein, human; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


48. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM: VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol; 2006 Feb;290(2):H560-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unlike during development, blood vessels in the adult are generally thought not to require VEGF for normal function.
  • However, VEGF is a survival factor for many tumor vessels, and there are clues that some normal blood vessels may also depend on VEGF.
  • In a study of 17 normal organs after VEGF inhibition, we found significant capillary regression in pancreatic islets, thyroid, adrenal cortex, pituitary, choroid plexus, small-intestinal villi, and epididymal adipose tissue.
  • The amount of regression was dose dependent and varied from organ to organ, with a maximum of 68% in thyroid, but was less in normal organs than in tumors in RIP-Tag2-transgenic mice or in Lewis lung carcinoma.
  • [MeSH-minor] Animals. Blood Pressure. Carcinoma, Lewis Lung / blood supply. Glucose Tolerance Test. Heart / physiology. Imidazoles. Indazoles / pharmacology. Islets of Langerhans / blood supply. Kidney / physiology. Mice. Mice, Inbred C57BL. Mice, Transgenic. Neoplasm Transplantation. Pancreatic Neoplasms / blood supply. Phenotype. Reference Values. Regeneration. Signal Transduction / drug effects. Signal Transduction / physiology. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H509-11 [16403945.001]
  • (PMID = 16172168.001).
  • [ISSN] 0363-6135
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL-24136; United States / NHLBI NIH HHS / HL / HL-59157; United States / NCI NIH HHS / CA / P50 CA-90270
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Indazoles; 0 / Vascular Endothelial Growth Factor A; C9LVQ0YUXG / axitinib; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


49. Boullu-Ciocca S, Achard V, Tassistro V, Dutour A, Grino M: Postnatal programming of glucocorticoid metabolism in rats modulates high-fat diet-induced regulation of visceral adipose tissue glucocorticoid exposure and sensitivity and adiponectin and proinflammatory adipokines gene expression in adulthood. Diabetes; 2008 Mar;57(3):669-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postnatal programming of glucocorticoid metabolism in rats modulates high-fat diet-induced regulation of visceral adipose tissue glucocorticoid exposure and sensitivity and adiponectin and proinflammatory adipokines gene expression in adulthood.
  • OBJECTIVE: Alterations of the perinatal environment, which lead to increased prevalence of the metabolic syndrome in adulthood, program an upregulation of systemic and/or adipose tissue glucocorticoid metabolism (11 beta-hydroxysteroid dehydrogenase type 1 [11 beta-HSD-1]-induced corticosterone reactivation).
  • We hypothesized that postnatal programming could modulate high-fat diet-induced adipose tissue dysregulation in adulthood.
  • RESULTS: Postnatal programming accentuated high-fat diet-induced overweight, insulin resistance, glucose intolerance, and decrease in circulating and epididymal adipose tissue adiponectin.
  • Postnatal programming or high-fat diet increased systemic corticosterone production, which was not further modified when both manipulations were associated.
  • Postnatal programming suppressed high-fat diet-induced decrease in mesenteric adipose tissue (MAT) glucocorticoid sensitivity and triggered high-fat diet-induced increase in MAT glucocorticoid exposure, subsequent to enhanced MAT 11 beta-HSD-1 gene expression.
  • MAT tumor necrosis factor (TNF)-alpha, TNF-receptor 1, interleukin (IL)-6, resistin, and plasminogen activator inhibitor-1 mRNAs were not changed by high-fat feeding in control rats and showed a large increase in programmed animals, with this effect further enhanced by high-fat diet for TNF-alpha and IL-6.
  • CONCLUSIONS: Our data show for the first time that postnatal manipulation programs high-fat diet-induced upregulation of MAT glucocorticoid exposure, sensitivity, and inflammatory status and therefore reveal the pivotal role of the environment during the perinatal period on the development of diet-induced adipose tissue dysregulation in adulthood.
  • [MeSH-major] Adipokines / metabolism. Adiponectin / metabolism. Adipose Tissue / metabolism. Diet. Dietary Fats / pharmacology. Glucocorticoids / metabolism

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Steroids.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057089.001).
  • [ISSN] 1939-327X
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / Adiponectin; 0 / Dietary Fats; 0 / Glucocorticoids; 0 / PPAR gamma; EC 1.1.1.146 / 11-beta-Hydroxysteroid Dehydrogenase Type 1; W980KJ009P / Corticosterone
  •  go-up   go-down


50. Uzun MA, Koksal N, Gunerhan Y, Celik A, Guneş P: Carcinosarcoma of the gallbladder: report of a case. Surg Today; 2009;39(2):168-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the gallbladder: report of a case.
  • Therefore the knowledge and experience regarding this disease is limited.
  • The pediculated polypoid tumor had filled the lumen, originating from the gallbladder fundus.
  • The tumor infiltrated the surrounding connective and adipose tissue overlapping the muscular layer of its primary site, but had not perforated the serosa nor invaded the liver.
  • The patient, who was treated only surgically, has remained healthy after 54 months of follow-up, which is the longest documented survival for this disease.
  • This case indicates that curative treatment of a tumor confined to the gallbladder without liver or serosa invasion, or lymph node involvement, is therefore possible.
  • [MeSH-major] Carcinosarcoma / diagnosis. Carcinosarcoma / surgery. Cholecystectomy / methods. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):e406-8 [14521442.001]
  • [Cites] World J Surg. 1991 May-Jun;15(3):315-21 [1853609.001]
  • [Cites] Semin Diagn Pathol. 1993 May;10(2):176-87 [8367625.001]
  • [Cites] Surg Today. 2005;35(2):101-5 [15674488.001]
  • [Cites] Pathol Int. 2004 Nov;54(11):866-71 [15533231.001]
  • [Cites] J Gastroenterol. 2002;37(11):966-71 [12483254.001]
  • [Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):818-21 [15985237.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):326-31 [1558412.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 Jun;17(6):683-5 [15879734.001]
  • [Cites] Surg Today. 2002;32(5):462-7 [12061703.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Cancer. 1982 Sep 15;50(6):1166-70 [7104957.001]
  • [Cites] Am J Surg. 1992 Apr;163(4):382-6 [1558279.001]
  • (PMID = 19198999.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


51. Chen CW, Chang WC, Lee HS, Ko KH, Chang CC, Huang GS: MRI features of lipoblastoma: differentiating from other palpable lipomatous tumor in pediatric patients. Clin Imaging; 2010 Nov-Dec;34(6):453-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI features of lipoblastoma: differentiating from other palpable lipomatous tumor in pediatric patients.
  • The purpose of this study was to describe the magnetic resonance imaging (MRI) features of lipoblastomas in pediatric patients and to differentiate them from other palpable benign lipomatous tumors.
  • The relatively specific MRI features of nonenhancing cystic change and enhancing soft tissue nodules seen in lipoblastoma may help to differentiate it from other types of lipomatous tumor in pediatric patients.
  • [MeSH-major] Lipoma / diagnosis. Magnetic Resonance Imaging / methods. Palpation. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21092875.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Caja S, Puerta M: White adipose tissue production and release of IL-6 and TNF-alpha do not parallel circulating and cerebrospinal fluid concentrations in pregnant rats. Horm Metab Res; 2008 Jun;40(6):375-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] White adipose tissue production and release of IL-6 and TNF-alpha do not parallel circulating and cerebrospinal fluid concentrations in pregnant rats.
  • IL-6 and TNF-alpha are synthesized in white adipose tissue both by adipocytes and by the stroma-vascular fraction.
  • During late pregnancy, white adipose tissue (WAT) mass increases and insulin sensitivity decreases.
  • To assess the involvement of both adipokines in such processes, we analyzed the tissue content and release of both adipokines in parametrial and subcutaneous WAT depots and their circulating and cerebrospinal fluid concentrations in nonpregnant rats and in pregnant rats by days 8, 15, and 19 of pregnancy.
  • The tissue content of both adipokines was enhanced 5-6 times by day 8 until the end of pregnancy in parametrial WAT, whereas the increase took place by day 15-19 in subcutaneous WAT.
  • No increase in tissue release was detected, suggesting a local action.
  • TNF-alpha was not detected in either serum or cerebrospinal fluid.
  • [MeSH-major] Adipose Tissue, White / metabolism. Interleukin-6 / metabolism. Intra-Abdominal Fat / metabolism. Pregnancy / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Pregnancy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18401835.001).
  • [ISSN] 0018-5043
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


53. Byerly MS, Simon J, Cogburn LA, Le Bihan-Duval E, Duclos MJ, Aggrey SE, Porter TE: Transcriptional profiling of hypothalamus during development of adiposity in genetically selected fat and lean chickens. Physiol Genomics; 2010 Jul 7;42(2):157-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differences in expression of genes associated with tumor necrosis factor (TNF) signaling were also noted.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Aug;17(8):1605-12 [12886250.001]
  • [Cites] Mol Neurobiol. 2003 Aug;28(1):51-64 [14514985.001]
  • [Cites] J Neurosci. 2004 Mar 17;24(11):2797-805 [15028773.001]
  • [Cites] Free Radic Biol Med. 2004 May 1;36(9):1155-62 [15082069.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1970-5 [15289464.001]
  • [Cites] J Nutr. 1981 Feb;111(2):325-35 [7007595.001]
  • [Cites] Poult Sci. 1982 Jan;61(1):117-21 [7088775.001]
  • [Cites] J Nutr. 1982 Oct;112(10):1961-73 [6750055.001]
  • [Cites] Nutr Rev. 1983 Apr;41(4):124-7 [6346152.001]
  • [Cites] Nutr Rev. 1984 Oct;42(10):354-6 [6390267.001]
  • [Cites] Poult Sci. 1985 Sep;64(9):1609-16 [3900971.001]
  • [Cites] Am J Physiol. 1985 Oct;249(4 Pt 2):R393-401 [3901782.001]
  • [Cites] Endocrinology. 1986 Dec;119(6):2635-41 [3536444.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4250-5 [3390820.001]
  • [Cites] Cancer Res. 1989 Nov 15;49(22):6280-4 [2804974.001]
  • [Cites] Poult Sci. 1990 Nov;69(11):1911-21 [2087450.001]
  • [Cites] Poult Sci. 1992 Aug;71(8):1237-50 [1523174.001]
  • [Cites] Curr Opin Lipidol. 1997 Aug;8(4):205-11 [9253536.001]
  • [Cites] Am J Physiol. 1997 Aug;273(2 Pt 2):R725-30 [9277561.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2907-12 [10077610.001]
  • [Cites] Obes Res. 2005 Mar;13(3):381-490 [15833932.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):131-40 [16098830.001]
  • [Cites] Mol Biol Evol. 2006 Feb;23(2):292-300 [16207936.001]
  • [Cites] Diabetes. 2006 Feb;55(2):412-20 [16443775.001]
  • [Cites] Physiol Genomics. 2006 May 16;25(3):414-25 [16493019.001]
  • [Cites] Physiol Genomics. 2006 May 16;25(3):514-24 [16554550.001]
  • [Cites] Obesity (Silver Spring). 2006 Apr;14(4):529-644 [16741264.001]
  • [Cites] Diabetes. 2006 Jul;55(7):1923-9 [16804059.001]
  • [Cites] Yonsei Med J. 2006 Oct 31;47(5):729-36 [17066518.001]
  • [Cites] PLoS Comput Biol. 2006 Jun 2;2(6):e54 [16741557.001]
  • [Cites] Brain Behav Immun. 2007 Jan;21(1):60-7 [15951155.001]
  • [Cites] Autoimmun Rev. 2007 Jan;6(3):176-82 [17289554.001]
  • [Cites] Metabolism. 2007 Jun;56(6):799-805 [17512313.001]
  • [Cites] J Physiol. 2007 Jul 1;582(Pt 1):379-92 [17495045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15075-80 [17724332.001]
  • [Cites] Cell Metab. 2007 Oct;6(4):252-4 [17908553.001]
  • [Cites] J Neurosci. 2008 Jan 2;28(1):264-78 [18171944.001]
  • [Cites] Nature. 1999 Nov 25;402(6760):411-3 [10586880.001]
  • [Cites] J Clin Invest. 2000 May;105(10):1345-52 [10811842.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Science. 2002 Aug 23;297(5585):1283-5 [12193771.001]
  • [Cites] Am J Hum Genet. 2008 Apr;82(4):809-21 [18313022.001]
  • [Cites] J Anim Sci. 2008 Nov;86(11):2888-96 [18599665.001]
  • [Cites] J Physiol. 2009 Jan 15;587(Pt 1):195-210 [19001049.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R1180-9 [19158410.001]
  • [Cites] J Hum Genet. 2009 Jun;54(6):324-30 [19343043.001]
  • (PMID = 20371548.001).
  • [ISSN] 1531-2267
  • [Journal-full-title] Physiological genomics
  • [ISO-abbreviation] Physiol. Genomics
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / F31-DK-743802; United States / NIMH NIH HHS / MH / MH-20048; United States / NIDDK NIH HHS / DK / F31 DK074380-02; United States / NIDDK NIH HHS / DK / F31 DK074380; United States / NIDDK NIH HHS / DK / F31 DK074380-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3032285
  •  go-up   go-down


54. Uji Y, Yamamoto H, Maeda K, Tsuchihashi H, Akabori H, Shimizu T, Endo Y, Shimomura I, Tani T: Adiponectin deficiency promotes the production of inflammatory mediators while severely exacerbating hepatic injury in mice with polymicrobial sepsis. J Surg Res; 2010 Jun 15;161(2):301-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adiponectin (APN), which is an adipose tissue-derived hormone, is known as an anti-inflammatory cytokine.
  • The plasma and hepatic levels of inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1), were measured before, at 24, and 48 h after CLP.
  • The administration of rosiglitazone significantly lowered the plasma levels of inflammatory mediators, including TNF-alpha, IL-6, and MCP-1, in WT mice but not in APN-KO mice during sepsis.
  • [MeSH-minor] Alanine Transaminase / blood. Alanine Transaminase / metabolism. Animals. Disease Models, Animal. Fibrinolytic Agents / therapeutic use. Inflammation / blood. Inflammation / physiopathology. Interleukin-6 / blood. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Microscopy, Confocal. Punctures. Receptors, CCR2 / blood. Tumor Necrosis Factor-alpha / blood

  • MedlinePlus Health Information. consumer health - Sepsis.
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19481767.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Fibrinolytic Agents; 0 / Inflammation Mediators; 0 / Interleukin-6; 0 / Receptors, CCR2; 0 / Thiazolidinediones; 0 / Tumor Necrosis Factor-alpha; 05V02F2KDG / rosiglitazone; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


55. Uenotsuchi T, Imafuku S, Moroi Y, Urabe K, Furue M: Large subcutaneous liposarcoma arising from the chest wall. Eur J Dermatol; 2005 Jan-Feb;15(1):43-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liposarcoma usually occurs in the deep soft tissue of the extremities and the retroperitoneum.
  • It rarely occurs in the cutaneous or subcutaneous tissues.
  • We describe the case of a subcutaneous liposarcoma in a 63-year-old man, which arose from the chest wall.
  • Magnetic resonance imaging showed a large subcutaneous tumor.
  • Incisional biopsy revealed mature adipose cells with a slight variation in size and shape; no lipoblasts were observed.
  • Therefore, at this stage we made the diagnosis of lipoma.
  • However, the histological study of the tumor specimen subsequently obtained by surgery, showed mature adipose cells, atypical cells with bizarre nuclei, and lipoblasts with scalloped-shaped nuclei.
  • We eventually diagnosed the tumor as a well-differentiated liposarcoma, adipocytic type (lipoma-like type).
  • [MeSH-major] Liposarcoma. Soft Tissue Neoplasms. Thoracic Wall

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701593.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


56. Varastehpour A, Radaelli T, Minium J, Ortega H, Herrera E, Catalano P, Hauguel-de Mouzon S: Activation of phospholipase A2 is associated with generation of placental lipid signals and fetal obesity. J Clin Endocrinol Metab; 2006 Jan;91(1):248-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine placental signals that translate into development of excess adipose tissue, we investigated the role of phospholipases A2 (PLA2) as targets of inflammatory mediators.
  • MAIN OUTCOME MEASURES: The primary outcomes were placenta PLA2 expression and fatty acid concentration.
  • RESULTS: Expression of PLA2G2A and PLA2G5, the main placenta phospholipases, was greater (P < 0.05) in placenta of obese compared with control neonates and was associated with increased 20:3 and 20:5 omega-3 polyunsaturated fatty acids.
  • CONCLUSION: Accumulation of omega-3 fatty acids through secretory PLA2 activation is associated with high neonatal adiposity.
  • [MeSH-minor] Adult. Cell Separation. Cells, Cultured. Enzyme Activation. Fatty Acids, Omega-3 / metabolism. Fatty Acids, Omega-6 / metabolism. Female. Humans. Infant, Newborn. Leptin / blood. Phospholipases A2. Pregnancy. RNA / biosynthesis. Tumor Necrosis Factor-alpha / metabolism


57. Karaki M, Kobayashi R, Mori N: Removal of an orbital apex hemangioma using an endoscopic transethmoidal approach: technical note. Neurosurgery; 2006 Jul;59(1 Suppl 1):ONSE159-60; discussion ONSE159-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tumor removal was performed in a patient with an intraconal cavernous hemangioma of approximately 15 mm in diameter.
  • By elevating the orbital fat, the tumor could be identified separately from the orbital contents.
  • CONCLUSION: An endoscopic transethmoidal approach, which requires no skin incision, is a minimally invasive surgery for retrobulbar orbital tumor, leading to excellent cosmetic results with less bleeding.
  • [MeSH-major] Craniotomy / methods. Endoscopy / methods. Ethmoid Bone / surgery. Hemangioma, Cavernous, Central Nervous System / surgery. Orbit / surgery. Orbital Neoplasms / surgery
  • [MeSH-minor] Adipose Tissue / anatomy & histology. Adipose Tissue / surgery. Female. Humans. Intraoperative Complications / prevention & control. Middle Aged. Oculomotor Muscles / anatomy & histology. Oculomotor Muscles / surgery. Ophthalmic Artery / pathology. Ophthalmic Artery / radiography. Ophthalmic Artery / surgery. Optic Nerve / anatomy & histology. Optic Nerve / blood supply. Optic Nerve / surgery. Paranasal Sinuses / anatomy & histology. Paranasal Sinuses / radiography. Paranasal Sinuses / surgery. Periosteum / anatomy & histology. Periosteum / surgery. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / physiopathology. Postoperative Hemorrhage / prevention & control. Preoperative Care / methods. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16888560.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Miyashita K: Function of marine carotenoids. Forum Nutr; 2009;61:136-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A nutrigenomic study revealed that fucoxanthin induces uncoupling protein 1 expression in white adipose tissue (WAT) mitochondria to lead to oxidation of fatty acids and heat production in WAT.
  • Fucoxanthin improves insulin resistance and decreases blood glucose level, at least in part, through the downregulation of tumor necrosis factor-alpha in WAT of animals.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASTAXANTHINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19367118.001).
  • [ISSN] 1660-0347
  • [Journal-full-title] Forum of nutrition
  • [ISO-abbreviation] Forum Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Xanthophylls; 06O0TC0VSM / fucoxanthin; 36-88-4 / Carotenoids; 8XPW32PR7I / astaxanthine
  • [Number-of-references] 29
  •  go-up   go-down


59. Nishida J, Ehara S, Shiraishi H, Tada H, Satoh T, Okada K, Shimamura T: Clinical findings of hibernoma of the buttock and thigh: rare involvements and extremely high uptake of FDG-PET. Med Sci Monit; 2009 Jul;15(7):CS117-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hibernoma is a rare adipose tissue tumor of the soft tissue and the term is derived from the histological similarities to the brown fat found in hibernating animals.
  • This was not typical of liposarcoma and suggestive of hibernoma.
  • Biopsy specimens revealed a proliferation of adipose cells with vacuolated granular eosinophilic cytoplasm.
  • CONCLUSIONS: While occurrences in the buttock or thigh are exceedingly rare, hibernoma should be included in the differential diagnosis of an adipose tissue tumor in the thigh, even though the imaging findings mimic liposarcoma.
  • A correct diagnosis should be established to prevent over-surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564831.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


60. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H: Plasma adiponectin and gastric cancer. Clin Cancer Res; 2005 Jan 15;11(2 Pt 1):466-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adiponectin is a peptide hormone secreted by adipose tissue, affecting the proliferation and insulin sensitivity of various types of cells.
  • RESULTS: Plasma adiponectin level was significantly lower in patients with gastric cancer than in healthy controls (9.1 +/- 6.2 versus 13.3 +/- 9.4 ng/mL, P < 0.01) and showed a significant modest inverse relation with the gastric cancer (odds ratio, 0.92; 95% confidence interval, 0.85-0.97; adjusted odds ratio, 0.89; 95% confidence interval, 0.84-0.95], although body mass index was not different.
  • Furthermore, adiponectin level tended to decrease as the tumor stage increased (stage I, 9.9 +/- 6.9 ng/mL; stage II, 8.7 +/- 5.5 ng/mL; stage III, 8.6 +/- 4.1 ng/mL; stage IV, 5.2 +/- 6.2 ng/mL; P = 0.34).
  • Interestingly, in 32 patients with undifferentiated cancer, serum adiponectin showed a negative correlation with pathologic findings such as tumor size, depth of invasion, as well as tumor stage (P < 0.05), but no correlation in the remaining 43 patients with differentiated cancer.
  • [MeSH-major] Intercellular Signaling Peptides and Proteins / blood. Stomach Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / etiology. Adiponectin. Body Mass Index. Carcinoma, Signet Ring Cell / blood. Carcinoma, Signet Ring Cell / etiology. Case-Control Studies. Cell Differentiation. Collagen / blood. Down-Regulation. Fasting. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Stomach / metabolism. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701829.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG 21418; United States / NCI NIH HHS / CA / R01 CA 1018447; United States / NIDDK NIH HHS / DK / T32 DK 07790
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Intercellular Signaling Peptides and Proteins; 9007-34-5 / Collagen
  •  go-up   go-down


61. Law IK, Xu A, Lam KS, Berger T, Mak TW, Vanhoutte PM, Liu JT, Sweeney G, Zhou M, Yang B, Wang Y: Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity. Diabetes; 2010 Apr;59(4):872-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The proinflammatory cytokines/adipokines produced from adipose tissue act in an autocrine and/or endocrine manner to perpetuate local inflammation and to induce peripheral insulin resistance.
  • Despite enlarged fat mass, inflammation and the accumulation of lipid peroxidation products are significantly attenuated in the adipose tissues of Lcn2-KO mice.
  • Adipose fatty acid composition of these mice varies significantly from that in wild-type animals.
  • The amounts of arachidonic acid (C20:4 n6) are elevated by aging and obesity and are paradoxically further increased in adipose tissue, but not skeletal muscle and liver of Lcn2-KO mice.
  • On the other hand, the expression and activity of 12-lipoxygenase, an enzyme responsible for metabolizing arachidonic acid, and the production of tumor necrosis factor-alpha (TNF-alpha), a critical insulin resistance-inducing factor, are largely inhibited by lipocalin-2 deficiency.
  • Lipocalin-2 stimulates the expression and activity of 12-lipoxygenase and TNF-alpha production in fat tissues.
  • CONCLUSIONS: Lipocalin-2 deficiency protects mice from developing aging- and obesity-induced insulin resistance largely by modulating 12-lipoxygenase and TNF-alpha levels in adipose tissue.
  • [MeSH-minor] 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid / metabolism. Adiponectin / metabolism. Adipose Tissue / metabolism. Animals. Blood Glucose / metabolism. Crosses, Genetic. Female. Glucose / metabolism. Insulin / blood. Insulin Resistance. Lipid Peroxidation. Lipids / blood. Lipocalins. Liver / metabolism. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Muscle, Skeletal / metabolism. Obesity / prevention & control. Receptors, Leptin / deficiency. Tumor Necrosis Factor-alpha / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gerontol A Biol Sci Med Sci. 1997 Jul;52(4):B190-5 [9224423.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):284-97 [11058769.001]
  • [Cites] Nature. 1997 Oct 9;389(6651):610-4 [9335502.001]
  • [Cites] J Intern Med. 1999 Jun;245(6):621-5 [10395191.001]
  • [Cites] Eur J Clin Invest. 1999 Sep;29(9):758-69 [10469164.001]
  • [Cites] Diabetes. 2005 Apr;54(4):917-27 [15793228.001]
  • [Cites] Lancet. 2005 Apr 2-8;365(9466):1231-8 [15811456.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1111-9 [15864338.001]
  • [Cites] J Allergy Clin Immunol. 2005 May;115(5):911-9; quiz 920 [15867843.001]
  • [Cites] J Lipid Res. 2005 Nov;46(11):2347-55 [16150820.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1834-9 [16446425.001]
  • [Cites] J Immunol. 2006 May 1;176(9):5559-66 [16622025.001]
  • [Cites] J Biol Chem. 2006 Jun 16;281(24):16391-400 [16621799.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24138-48 [16798734.001]
  • [Cites] Nat Rev Immunol. 2006 Oct;6(10):772-83 [16998510.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):9-24 [11058743.001]
  • [Cites] Obesity (Silver Spring). 2009 Sep;17(9):1657-63 [19521344.001]
  • [Cites] Diabetes. 2001 Aug;50(8):1821-7 [11473044.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42077-83 [11546817.001]
  • [Cites] Diabetes. 2002 Jun;51(6):1876-83 [12031976.001]
  • [Cites] Mol Cell Proteomics. 2002 Mar;1(3):213-22 [12096121.001]
  • [Cites] Diabetes. 2002 Nov;51(11):3176-88 [12401708.001]
  • [Cites] Gene. 2002 Oct 16;299(1-2):95-100 [12459256.001]
  • [Cites] J Clin Invest. 2003 Jul;112(1):91-100 [12840063.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1796-808 [14679176.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1821-30 [14679177.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Dec;27 Suppl 3:S53-5 [14704746.001]
  • [Cites] Endocrinology. 2004 Feb;145(2):487-94 [14592951.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Nov;287(5):E934-8 [15213061.001]
  • [Cites] J Chromatogr. 1979 Mar 1;162(3):261-71 [528594.001]
  • [Cites] Oncogene. 1989 May;4(5):601-8 [2542864.001]
  • [Cites] Biochim Biophys Acta. 1991 Oct 26;1095(2):145-52 [1932134.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10425-32 [7683678.001]
  • [Cites] J Immunol. 1993 Aug 1;151(3):1535-47 [8335946.001]
  • [Cites] Physiol Behav. 1995 Feb;57(2):319-23 [7716210.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2409-15 [7738205.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2233-41 [8570173.001]
  • [Cites] Clin Chem. 2007 Jan;53(1):34-41 [17040956.001]
  • [Cites] Clin Chem. 2007 Jan;53(1):5-7 [17202496.001]
  • [Cites] Diabetes. 2007 Oct;56(10):2533-40 [17639021.001]
  • [Cites] Diabetes. 2007 Nov;56(11):2668-72 [17601989.001]
  • [Cites] J Anim Sci. 2008 Apr;86(14 Suppl):E94-104 [17940160.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G948-62 [18258795.001]
  • [Cites] Mol Endocrinol. 2008 Jun;22(6):1416-26 [18292240.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1065-75 [18780776.001]
  • [Cites] IUBMB Life. 2009 Jan;61(1):47-55 [18839419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3913-8 [19237579.001]
  • [Cites] J Mol Med (Berl). 2009 Aug;87(8):803-13 [19466389.001]
  • [Cites] Diabetes. 1997 Sep;46(9):1526-31 [9287059.001]
  • (PMID = 20068130.001).
  • [ISSN] 1939-327X
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Adiponectin; 0 / Blood Glucose; 0 / Insulin; 0 / Lipids; 0 / Lipocalins; 0 / Oncogene Proteins; 0 / Receptors, Leptin; 0 / Tumor Necrosis Factor-alpha; 126469-30-5 / Lcn2 protein, mouse; 59985-28-3 / 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; IY9XDZ35W2 / Glucose
  • [Other-IDs] NLM/ PMC2844835
  •  go-up   go-down


62. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw; 2006 Mar;17(1):4-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It now appears that, in most obese patients, obesity is associated with a low-grade inflammation of white adipose tissue (WAT) resulting from chronic activation of the innate immune system and which can subsequently lead to insulin resistance, impaired glucose tolerance and even diabetes.
  • In obesity, WAT is characterized by an increased production and secretion of a wide range of inflammatory molecules including TNF-alpha and interleukin-6 (IL-6), which may have local effects on WAT physiology but also systemic effects on other organs.
  • Several factors derived not only from adipocytes but also from infiltrated macrophages probably contribute to the pathogenesis of insulin resistance.
  • TNF-alpha is overproduced in adipose tissue of several rodent models of obesity and has an important role in the pathogenesis of insulin resistance in these species.
  • IL-6 production by human adipose tissue increases during obesity.
  • Adiponectin is highly expressed in WAT, and circulating adiponectin levels are decreased in subjects with obesity-related insulin resistance, type 2 diabetes and coronary heart disease.
  • Adiponectin inhibits liver neoglucogenesis and promotes fatty acid oxidation in skeletal muscle.
  • [MeSH-major] Adipose Tissue / immunology. Diabetes Mellitus, Type 2 / complications. Insulin Resistance / physiology. Lipid Metabolism. Obesity / complications
  • [MeSH-minor] Adiponectin / biosynthesis. Adiponectin / blood. Humans. Inflammation / complications. Inflammation / immunology. Interleukin-6 / biosynthesis. Interleukin-6 / blood. Leptin / biosynthesis. Leptin / blood. Macrophages / immunology. Resistin / biosynthesis. Resistin / blood. Signal Transduction / physiology. Tumor Necrosis Factor-alpha / biosynthesis


63. Sebastian BM, Kang L, Chen X, Nagy LE: Methods to investigate the effects of chronic ethanol on adipocytes. Methods Mol Biol; 2008;447:357-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic ethanol consumption dysregulates glucose and lipid homeostasis, is associated with insulin resistance, and alters serum levels of adipokines including adiponectin and tumor necrosis factor-alpha.
  • However, the mechanisms involved in these chronic ethanol-induced pathologies are not fully understood.
  • Adipose tissue has been implicated as an important contributor to chronic ethanol-induced disease states and, therefore, the effects of chronic ethanol feeding in rats on adipocytes has been investigated.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18369929.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / AA-11876
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Adipoq protein, rat; 0 / Adrenergic beta-Agonists; 0 / Insulin; 3K9958V90M / Ethanol; IY9XDZ35W2 / Glucose; L628TT009W / Isoproterenol
  •  go-up   go-down


64. Irahara N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S: Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer. Int J Cancer; 2006 Apr 15;118(8):1915-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of the present study was to study the aromatase mRNA expression as well as promoter usage (I.4, I.3, PII and I.7) in axillary adipose tissue (AA), mammary adipose tissue (MA), breast tumor tissue (BT) and adjacent normal breast tissue (NB), and to study the relationship between aromatase mRNA expression and tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and cyclooxygenase (COX)-2 mRNA expression.
  • Estrogen receptor-alpha (ER-alpha) positive tumors showed a higher percentage of promoter I.7 usage than ER-alpha negative tumors with a marginal significance (p=0.05), and tumor with high microvessel counts tended (p=0.06) to show a higher percentage of promoter I.7 usage than those with low microvessel counts.
  • There was a significant association between aromatase mRNA levels and TNF-alpha, IL-6 or COX-2 mRNA levels in BT, AA and MA but not in NB.
  • It has also been suggested that angiogenesis might stimulate the growth of ER-alpha positive tumors through the enhanced transcription of aromatase from promoter I.7 in endothelial cells in BT, and that TNF-alpha, IL-6 and COX-2 might be implicated in the up-regulation of aromatase mRNA in BT, AA and MA but not in NB.
  • [MeSH-major] Aromatase / biosynthesis. Breast Neoplasms / genetics. Cyclooxygenase 2 / biosynthesis. Interleukin-6 / biosynthesis. Tumor Necrosis Factor-alpha / biosynthesis
  • [MeSH-minor] Adipose Tissue / physiology. Breast / physiology. Female. Gene Expression Profiling. Humans. Neovascularization, Pathologic. Polymerase Chain Reaction. Promoter Regions, Genetic. RNA, Messenger / biosynthesis. Tumor Cells, Cultured. Up-Regulation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16287071.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; EC 1.14.14.1 / Aromatase; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


65. Sou S, Nomura H, Takaki Y, Nagahama T, Matsubara F, Matsui T, Yao T: Hemorrhagic duodenal lipoma managed by endoscopic resection. J Gastroenterol Hepatol; 2006 Feb;21(2):479-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An upper gastrointestinal roentgenologic study revealed a submucosal tumor with a smooth surface and a stalk measuring 50 mm at the third part of the duodenum.
  • Endoscopy depicted it as a yellowish submucosal tumor.
  • Based on computed tomography and fluoroscopy of the small intestine, a diagnosis of duodenal lipoma was made.
  • The tumor was endoscopically polypectomized using a 2-channel scope.
  • Photomicrographic findings included a tumor that was composed of mature adipose tissue in the submucosa, which coincided with a diagnosis of lipoma.
  • Lipoma is a benign tumor; and if the lesion is found to be pedunculated and an endoscope can reach it for treatment, minimally invasive endoscopic procedures should be selected.
  • [MeSH-major] Duodenal Neoplasms / complications. Electrocoagulation / methods. Endoscopy, Gastrointestinal. Gastrointestinal Hemorrhage / surgery. Lipoma / complications

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509883.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


66. Zhao M, Dumur CI, Holt SE, Beckman MJ, Elmore LW: Multipotent adipose stromal cells and breast cancer development: Think globally, act locally. Mol Carcinog; 2010 Nov;49(11):923-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multipotent adipose stromal cells and breast cancer development: Think globally, act locally.
  • It has long been appreciated that stromal cells within the breast tumor microenvironment contribute to mammary carcinogenesis.
  • However, to date, very little is known regarding the role of local adipose-derived stromal cells (ASCs) in the development of breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • [Cites] J Natl Cancer Inst. 2000 Mar 15;92(6):443 [10716955.001]
  • [Cites] Stem Cells Dev. 2010 Oct;19(10):1485-99 [20050811.001]
  • [Cites] AJR Am J Roentgenol. 2001 Sep;177(3):573-7 [11517049.001]
  • [Cites] Mol Biol Cell. 2002 Dec;13(12):4279-95 [12475952.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 12;309(1):232-40 [12943687.001]
  • [Cites] J Pathol. 2003 Oct;201(2):221-8 [14517839.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603 [15523088.001]
  • [Cites] J Cell Mol Med. 2005 Jan-Mar;9(1):208-21 [15784178.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2637-43 [15814644.001]
  • [Cites] Stem Cells. 2006 May;24(5):1294-301 [16410387.001]
  • [Cites] Stem Cells. 2007 Apr;25(4):818-27 [17420225.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4331-9 [18519693.001]
  • [Cites] Laryngoscope. 2009 Jan;119(1):91-101 [19117295.001]
  • [Cites] Carcinogenesis. 2009 Apr;30(4):589-97 [19181699.001]
  • [Cites] Cytotherapy. 2009;11(3):289-98, 1 p following 298 [19308770.001]
  • [Cites] Endocrinology. 2009 Jun;150(6):2537-42 [19372199.001]
  • [Cites] Oncogene. 2009 Jul 30;28(30):2745-55 [19483720.001]
  • [Cites] Cancer Lett. 2009 Oct 18;284(1):80-5 [19427114.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):1133-40 [11381097.001]
  • (PMID = 20842668.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA016059-21; United States / NCI NIH HHS / CA / P30CA16059; United States / NCI NIH HHS / CA / K01 CA105050-05; United States / NCI NIH HHS / CA / KO1 CA105050-01A131; United States / NINDS NIH HHS / NS / P30 NS047463; United States / NCI NIH HHS / CA / P30 CA016059-21; United States / NCI NIH HHS / CA / K01 CA105050; United States / NINDS NIH HHS / NS / P30 NS047463-09; United States / NCI NIH HHS / CA / P30 CA016059; United States / NINDS NIH HHS / NS / 5P30NS047463
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS347994; NLM/ PMC3276248
  •  go-up   go-down


67. Simpfendorfer CS, Ilaslan H, Davies AM, James SL, Obuchowski NA, Sundaram M: Does the presence of focal normal marrow fat signal within a tumor on MRI exclude malignancy? An analysis of 184 histologically proven tumors of the pelvic and appendicular skeleton. Skeletal Radiol; 2008 Sep;37(9):797-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the presence of focal normal marrow fat signal within a tumor on MRI exclude malignancy? An analysis of 184 histologically proven tumors of the pelvic and appendicular skeleton.
  • OBJECTIVE: The aim of this study was to determine if the presence of focal normal bone marrow fat signal within a tumor on magnetic resonance imaging excludes malignancy.
  • MATERIALS AND METHODS: One hundred eighty-four histologically proven tumors with available magnetic resonance imaging (MRI) of the appendicular skeleton and pelvis from 184 patients were collected and reviewed at two separate institutions.
  • There were 111 malignant and 73 benign tumors.
  • Two radiologists at each institution, blinded to the diagnosis, reviewed the MRIs independently and reported the presence or absence of normal marrow fat signal within the tumor based upon T1-weighted imaging without fat suppression and T2-weighted imaging with fat suppression and/or short inversion-time inversion recovery (STIR).
  • For each institution, a Fisher's exact test was used to compare the frequency of focal normal marrow fat signal in benign and malignant tumors.
  • Reader consensus at site 1 identified normal marrow fat signal within 1 of 50 (2.0%) malignant and three of 14 (21.4%) benign tumors.
  • Reader consensus at site 2 identified normal marrow fat signal within three of 61 (4.9%) malignant and 14 of 59 (23.7%) benign tumors.
  • CONCLUSION: The presence of focal normal marrow signal within a tumor is highly suggestive of a benign tumor.
  • [MeSH-major] Adipose Tissue / pathology. Bone Marrow / pathology. Bone Neoplasms / pathology. Magnetic Resonance Imaging / methods. Pelvic Bones / pathology
  • [MeSH-minor] Algorithms. Bayes Theorem. Female. Humans. Male. Neoplasm Metastasis. Predictive Value of Tests. Reproducibility of Results


68. Kim KA, Ka SO, Moon WS, Yi HK, Lee YH, Kwon KB, Park JW, Park BH: Effect of dermcidin, an antimicrobial peptide, on body fat mobilization in normal mice. J Endocrinol; 2008 Jul;198(1):111-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The plasma triglyceride level was decreased, whereas the free fatty acid and glycerol levels were increased in the Ad-DCD-injected group.
  • Epididymal adipose tissues obtained from Ad-DCD-injected mice consisted of smaller adipocytes than tissues obtained from Ad-beta-gal-injected mice.
  • The gene expression profiles revealed an upregulation of hormone-sensitive lipase and adipose fatty acid-binding protein, both of which are involved in adipocyte lipolysis, in Ad-DCD-injected mice, and this lipolytic effect of DCD paralleled the increase of circulating tumor necrosis factor-alpha (TNF-alpha) level that was observed.
  • The perilipin levels in adipose tissue were decreased in Ad-DCD-injected mice when compared with those of the control mice.
  • Taken together, these results suggest that DCD-mediated body fat reduction might occur as a result of TNF-alpha-induced downregulation of perilipin in adipose tissue.
  • [MeSH-major] Adipose Tissue / metabolism. Peptides / physiology
  • [MeSH-minor] Adenoviridae / genetics. Animals. Carrier Proteins. Cells, Cultured. Fatty Acids, Nonesterified / blood. Lipid Metabolism. Male. Mice. Mice, Inbred ICR. Phosphoproteins / blood. Triglycerides / blood. Tumor Necrosis Factor-alpha / blood. Tumor Necrosis Factor-alpha / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467379.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Fatty Acids, Nonesterified; 0 / Peptides; 0 / Phosphoproteins; 0 / Triglycerides; 0 / Tumor Necrosis Factor-alpha; 0 / dermcidin; 0 / perilipin 1
  •  go-up   go-down


69. Kralisch S, Sommer G, Deckert CM, Linke A, Bluher M, Stumvoll M, Fasshauer M: Adipokines in diabetes and cardiovascular diseases. Minerva Endocrinol; 2007 Sep;32(3):161-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, leptin, tumor necrosis factor a, interleukin-6, monocyte chemoattractant protein-1, and plasminogen activator inhibitor-1 are upregulated in obesity and contribute to the development of diabetes and vascular disease.
  • [MeSH-minor] Adiponectin / physiology. Adipose Tissue / physiopathology. Animals. Atherosclerosis / physiopathology. Chemokine CCL2 / physiology. Humans. Inflammation / physiopathology. Interleukin-6 / physiology. Leptin / physiology. Metabolic Syndrome X / physiopathology. Mice. Obesity / physiopathology. Plasminogen Activator Inhibitor 1 / physiology. Species Specificity. Tumor Necrosis Factor-alpha / physiology

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17912155.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adipokines; 0 / Adiponectin; 0 / Chemokine CCL2; 0 / Interleukin-6; 0 / Leptin; 0 / Plasminogen Activator Inhibitor 1; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


70. de Moraes M, de Matos FR, de Carvalho CP, de Medeiros AM, de Souza LB: Sialolipoma in minor salivary gland: case report and review of the literature. Head Neck Pathol; 2010 Sep;4(3):249-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sialolipoma is a rare benign neoplasm characterized by a well-circumscribed mass composed of neoplastic mature adipose tissue and non-neoplastic salivary gland elements.
  • Microscopically, the tumor was well-circumscribed consisting of lobular proliferation of the lipomatous tissue with thin fibrous tissue septa containing clustered salivary gland elements.
  • Both the glandular and adipose components were found in almost equal proportion.
  • No atypia in the adipose tissue was observed.
  • The definitive diagnosis was sialolipoma.
  • The age distribution was from 27 to 84 years (mean, 61.6 years) and the tumor size ranged from 0.9 to 4 cm (mean, 1.7 cm).
  • The most frequently reported clinical presentation was of a painless swelling (56.3%).
  • [MeSH-major] Lipoma / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2001 Jan;38(1):30-6 [11135044.001]
  • [Cites] Ann Diagn Pathol. 2001 Aug;5(4):207-15 [11510003.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Feb;32(1):49-53 [12653233.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Oct;98(4):441-50 [15472660.001]
  • [Cites] Kaohsiung J Med Sci. 2004 Aug;20(8):410-4 [15473653.001]
  • [Cites] Quintessence Int. 2009 Jan;40(1):79-85 [19159027.001]
  • [Cites] J Oral Pathol Med. 2007 Oct;36(9):558-62 [17850441.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Dec;104(6):809-13 [17482843.001]
  • [Cites] Oral Maxillofac Surg. 2009 Jun;13(2):109-13 [19347375.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Oct;108(4):571-6 [19699118.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2010 Mar;267(3):459-65 [19562364.001]
  • [Cites] J Oral Pathol Med. 2006 Jul;35(6):376-8 [16762019.001]
  • (PMID = 20563675.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2923305
  •  go-up   go-down


71. Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM: Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat; 2010 Jan;119(2):367-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients.
  • Adiopcyte fatty acid binding-protein(A-FABP) is another protein found in adipose tissue;therefore, we investigated the association of A-FABP with the occurrence and prognosis of breast cancer.
  • Serum levels ofA-FABP, leptin, and adiponectin were measured, and their relationship to body-mass-index (BMI), breast cancer, and tumor characteristics were analyzed; logistic regression model was adjusted to age, BMI, menopausal status, use of Hormone Replacement Therapy (HRT), and family history of breast cancer.
  • Independent of obesity, the serum A-FABP levels were significantly higher in breast cancer patients (34.65 ng/ml) than in healthy controls(24.47 ng/ml), P.0001; the odds ratio (1.038, P.05,95% confidence interval 1.001-1.72) showed a significant association of A-FABP with breast cancer risk.
  • Concerning tumor characteristics,A-FABP was positively connected with tumor size (T C 2 cm, P.05) and nodal-status (P.05).Our study reveals that high A-FABP serum levels are associated with obesity, breast cancer risk, and adverse tumor characteristics.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / etiology. Fatty Acid-Binding Proteins / blood. Obesity / complications
  • [MeSH-minor] Adiponectin / blood. Adult. Aged. Body Mass Index. Case-Control Studies. Female. Humans. Leptin / blood. Logistic Models. Middle Aged. Neoplasm Staging. Odds Ratio. Postmenopause. Predictive Value of Tests. Premenopause. Risk Assessment. Risk Factors. Treatment Outcome. Up-Regulation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19842034.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / Adiponectin; 0 / Biomarkers, Tumor; 0 / FABP4 protein, human; 0 / Fatty Acid-Binding Proteins; 0 / Leptin
  •  go-up   go-down


72. Siddiqui MK, Jyoti, Singh S, Mehrotra PK, Singh K, Sarangi R: Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: an Indian study. Environ Int; 2006 Jul;32(5):630-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: an Indian study.
  • Fifty women residing in and around New Delhi, India and identified to have benign (25 nos.) and malignant (25 nos.) breast lesions were studied for the first time to access the association between environmental exposure to lead and risk of breast cancer and to determine the potential of changes in trace elements concentration as a diagnostic marker and/or its etiological involvement in the disease.
  • Blood, tumor tissue and breast adipose tissue from tumor free area from each patient of the two groups, collected at the time of lumpectomy or mastectomy (only blood sample was collected from disease free control group), were analyzed to determine the concentration of Pb, Zn, Cu, Fe and Ca using Atomic Absorption Spectrometry.
  • Lead level was also higher in tumor tissue when compared with their respective normal tumor free breast tissue, though non-significant, in both benign and malignant cases.
  • Furthermore, these metals were also higher in tumor of malignant and benign cases as compared to normal tumor free breast tissue, many of them statistically significant (p<0.05/0.01/0.001).
  • However, Cu level was insignificantly lower in the blood and tumor tissue of malignant cases when compared with their benign counterparts while it was significantly higher (p<0.05) in tumor of benign cases when compared with those of their respective normal tumor free breast tissue.
  • There were statistically significant correlations between lead and trace element levels only in normal tumor free breast tissue of benign and malignant cases (r=0.41-0.73; p<0.05-0.001) but neither in blood nor tumor tissue of the two groups.
  • Further, modulation of trace elements level in both benign and malignant breast diseases patients may be of potential to be used as diagnostic marker of the disease process and its possible relationship etiologically.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Mammary Glands, Human / metabolism. Trace Elements / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580070.001).
  • [ISSN] 0160-4120
  • [Journal-full-title] Environment international
  • [ISO-abbreviation] Environ Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Trace Elements
  •  go-up   go-down


73. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH: The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol; 2007 May;156(5):595-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adipocytokines are hormones secreted by adipose tissue and contribute to insulin resistance.
  • METHODS: Leptin, adiponectin, resistin, tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and CRP levels were measured before and after each treatment phase.


74. Boone JM, Kwan AL, Yang K, Burkett GW, Lindfors KK, Nelson TR: Computed tomography for imaging the breast. J Mammary Gland Biol Neoplasia; 2006 Apr;11(2):103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subjective evaluation of the breast CT images reveals excellent anatomical detail, good depiction of microcalcifications, and exquisite visualization of the soft tissue components of the tumor when contrasted against adipose tissues.
  • The use of iodine contrast injection dramatically enhances the visualization of tumors.
  • [MeSH-major] Breast Neoplasms / diagnostic imaging. Diffusion of Innovation. Image Processing, Computer-Assisted / instrumentation. Mammography / instrumentation. Tomography Scanners, X-Ray Computed / standards. Tomography, Spiral Computed / instrumentation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Oncol Rep. 2006 Jan;8(1):7-13 [16464397.001]
  • [Cites] Breast J. 2003 Sep-Oct;9(5):403-8 [12968962.001]
  • [Cites] AJR Am J Roentgenol. 2004 Oct;183(4):1149-57 [15385322.001]
  • [Cites] Comput Med Imaging Graph. 2004 Jul;28(5):235-46 [15249069.001]
  • [Cites] Radiology. 1979 Sep;132(3):647-52 [472242.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Jun;23 (6):696-703 [15191144.001]
  • [Cites] AJR Am J Roentgenol. 1979 Dec;133(6):1143-9 [116508.001]
  • [Cites] Phys Med Biol. 2004 Jun 7;49(11):2183-95 [15248571.001]
  • [Cites] J Clin Ultrasound. 2003 Jun;31(5):227-38 [12767017.001]
  • [Cites] Int J Fertil Womens Med. 2005 Nov-Dec;50(6):281-4 [16526420.001]
  • [Cites] Opt Lett. 2005 Nov 1;30(21):2915-7 [16279468.001]
  • [Cites] Radiol Clin North Am. 2000 Jul;38(4):625-51 [10943268.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):1045-53 [16244803.001]
  • [Cites] IEEE Trans Ultrason Ferroelectr Freq Control. 2005 Nov;52(11):2011-22 [16422413.001]
  • [Cites] Semin Roentgenol. 1978 Jul;13(3):267-75 [210522.001]
  • [Cites] N Engl J Med. 2004 Jul 29;351(5):427-37 [15282350.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):923-4 [16087089.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1111-2 [15451209.001]
  • [Cites] Med Phys. 2004 Feb;31(2):226-35 [15000608.001]
  • [Cites] Med Phys. 2004 Sep;31(9):2636-47 [15487747.001]
  • [Cites] Breast Cancer Res. 2005;7(5):215-9 [16168141.001]
  • [Cites] Lancet. 2005 May 21-27;365(9473):1769-78 [15910949.001]
  • [Cites] Isr Med Assoc J. 2005 Nov;7(11):700-3 [16308991.001]
  • [Cites] J Nucl Med. 2003 Apr;44(4):583-93 [12679403.001]
  • [Cites] Breast Cancer. 2005;12 (4):267-71 [16286906.001]
  • [Cites] Radiology. 1993 Aug;188(2):297-301 [8327668.001]
  • [Cites] Radiology. 1997 Nov;205(2):399-406 [9356620.001]
  • [Cites] Surg Technol Int. 2005;14 :51-6 [16525954.001]
  • [Cites] Med Phys. 2002 May;29(5):869-75 [12033583.001]
  • [Cites] Phys Med Biol. 2003 Jul 21;48(14 ):2217-28 [12894980.001]
  • [Cites] Acad Radiol. 2000 Dec;7(12 ):1085-97 [11131053.001]
  • [Cites] Med Phys. 2005 Sep;32(9):2967-75 [16266111.001]
  • [Cites] Med Phys. 2005 Dec;32(12 ):3767-76 [16475776.001]
  • [Cites] Phys Med Biol. 2006 Mar 7;51(5):1283-97 [16481694.001]
  • [Cites] Cancer Imaging. 2006 Jan 31;6:4-6 [16478698.001]
  • [Cites] Mayo Clin Proc. 1977 Mar;52(3):181-5 [320404.001]
  • [Cites] Med Phys. 2002 May;29(5):755-70 [12033572.001]
  • [Cites] Technol Cancer Res Treat. 2004 Oct;3(5):437-41 [15453808.001]
  • [Cites] Radiol Manage. 2005 Sep-Oct;27(5):25-31 [16294583.001]
  • [Cites] J Comput Assist Tomogr. 1996 Mar-Apr;20(2):179-84 [8606220.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):652-6 [14760380.001]
  • [Cites] Breast Cancer Res. 2005;7(6):279-85 [16457705.001]
  • [Cites] Med Phys. 2004 Apr;31(4):800-13 [15124997.001]
  • [Cites] Comput Med Imaging Graph. 2005 Jan;29(1):1-14 [15710536.001]
  • [Cites] IEEE Trans Med Imaging. 2000 Sep;19(9):949-63 [11127608.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Jul;24(7):868-77 [16011316.001]
  • [Cites] Technol Cancer Res Treat. 2005 Oct;4(5):471-82 [16173819.001]
  • [Cites] Ultrasound Med Biol. 2006 Mar;32(3):387-96 [16530097.001]
  • [Cites] Appl Opt. 2006 Feb 10;45(5):1072-8 [16512551.001]
  • [Cites] Radiology. 2001 Dec;221(3):657-67 [11719660.001]
  • [Cites] Eur Radiol. 2002 Dec;12(12):3018-22 [12439585.001]
  • [Cites] Phys Med Biol. 2004 Dec 21;49(24):5433-44 [15724534.001]
  • [Cites] Radiol Med. 2002 Nov-Dec;104(5-6):443-50 [12589266.001]
  • [Cites] Radiol Clin North Am. 2000 Jul;38(4):861-9, x [10943283.001]
  • [Cites] Med Phys. 2003 Jul;30(7):1694-705 [12906186.001]
  • [Cites] Technol Cancer Res Treat. 2005 Oct;4(5):497-512 [16173821.001]
  • (PMID = 17053979.001).
  • [ISSN] 1083-3021
  • [Journal-full-title] Journal of mammary gland biology and neoplasia
  • [ISO-abbreviation] J Mammary Gland Biol Neoplasia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 89260; United States / NIBIB NIH HHS / EB / EB 002138
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


75. Mentzel T, Toennissen J, Rütten A, Schaller J: Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location. Virchows Arch; 2005 Mar;446(3):300-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location.
  • Lipomatous tumours, both benign and malignant, arising on the hands are uncommon.
  • We present a rare atypical lipomatous tumour with spindle cell features (synonym: well-differentiated spindle cell liposarcoma) arising on the left palm of a 54-year-old male patient.
  • The neoplasm presented as a long-standing, exophytic neoplasm measuring 9 x 9 cm.
  • The well-circumscribed neoplasm was completely excised, and margins were tumour free.
  • Histologically, the neoplasm showed features closely resembling spindle cell lipoma, being composed of mature adipocytic cells associated with bland, neuroid spindle cells staining positively for CD34.
  • However, focally, atypia of adipocytic and stromal cells as well as scattered lipoblasts were noted, and immunohistochemical stainings showed focal overexpression of MDM 2 and CDK4.
  • Aypical lipomatous tumour with spindle cell features may arise very rarely in palmar location and has to be distinguished from a number of benign and malignant mesenchymal neoplasms.
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1995;427(4):353-63 [8548119.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1192-9 [11106076.001]
  • [Cites] Am J Dermatopathol. 2000 Dec;22(6):496-502 [11190440.001]
  • [Cites] Cancer. 1975 Nov;36(5):1852-9 [1192370.001]
  • [Cites] Am J Clin Oncol. 2001 Feb;24(1):81-4 [11232956.001]
  • [Cites] Am Surg. 1975 Feb;41(2):117-20 [1122062.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):126-33 [7459800.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):30-41 [9892106.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 2000 Jun;34(2):185-7 [10900638.001]
  • [Cites] Ann Diagn Pathol. 2001 Oct;5(5):255-66 [11598853.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1182-9 [8827023.001]
  • [Cites] Acta Orthop Belg. 1994;60(3):334-5 [7992615.001]
  • [Cites] J Bone Joint Surg Am. 1994 Sep;76(9):1360-2 [8077265.001]
  • [Cites] Ann Diagn Pathol. 2000 Dec;4(6):354-60 [11149965.001]
  • [Cites] Gan No Rinsho. 1989 Feb;35(3):437-41 [2926990.001]
  • [Cites] J Hand Surg Am. 1989 Jul;14(4):700-4 [2754203.001]
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):83-93 [12004355.001]
  • [Cites] Am J Surg Pathol. 1994 Sep;18(9):913-21 [8067512.001]
  • [Cites] Ann Plast Surg. 1983 Nov;11(5):431-3 [6651174.001]
  • [Cites] Cutis. 1987 Jul;40(1):29-32 [3665587.001]
  • [Cites] J Bone Joint Surg Am. 1965 Jun;47:727-40 [14299665.001]
  • (PMID = 15719245.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Elks CM, Francis J: Central adiposity, systemic inflammation, and the metabolic syndrome. Curr Hypertens Rep; 2010 Apr;12(2):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inflammation of central adipose tissue leads to adipokine production, followed by secretion of adipokines into the general circulation to contribute to the overall inflammatory condition.
  • [MeSH-minor] Adipokines / biosynthesis. Adiponectin. C-Reactive Protein. Cytokines. Diet. Humans. Insulin Resistance. Interleukins. Leptin. Life Style. NF-kappa B. Nutritional Status. Risk Factors. Serine. Threonine. Tumor Necrosis Factor-alpha

  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 2;354(1):45-9 [17210129.001]
  • [Cites] J Am Soc Nephrol. 2004 Nov;15(11):2792-800 [15504932.001]
  • [Cites] Diabetologia. 2006 Sep;49(9):2162-73 [16865359.001]
  • [Cites] Diabetes Metab. 2008 Feb;34(1):2-11 [18093861.001]
  • [Cites] Diabetes Res Clin Pract. 2008 Feb;79(2):330-6 [17964679.001]
  • [Cites] Int J Obes (Lond). 2010 Jan;34(1):165-71 [19823181.001]
  • [Cites] Metabolism. 2009 Jun;58(6):860-6 [19375766.001]
  • [Cites] Mol Cell Endocrinol. 2010 Jan 15;314(1):1-16 [19682539.001]
  • [Cites] Obesity (Silver Spring). 2009 Nov;17(11):1994-2002 [19424163.001]
  • [Cites] Diabetes. 2002 Jul;51(7):2199-206 [12086950.001]
  • [Cites] Am J Physiol Renal Physiol. 2009 Feb;296(2):F298-305 [19073636.001]
  • [Cites] Clin Cornerstone. 2009;9(4):30-40; discussion 41-2 [19789062.001]
  • [Cites] Metabolism. 2004 Jul;53(7):852-7 [15254876.001]
  • [Cites] J Clin Invest. 2006 Nov;116(11):3015-25 [17053832.001]
  • [Cites] FASEB J. 2006 Jul;20(9):1540-2 [16754744.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):1023-33 [17164304.001]
  • [Cites] Prog Lipid Res. 2008 Sep;47(5):307-18 [18396172.001]
  • [Cites] Pflugers Arch. 2007 Dec;455(3):479-92 [17609976.001]
  • [Cites] Hepatology. 2009 Jan;49(1):87-96 [19053047.001]
  • [Cites] Obesity (Silver Spring). 2008 Apr;16(4):869-74 [18277389.001]
  • [Cites] Annu Rev Physiol. 2000;62:413-37 [10845097.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Sep;293(3):E656-65 [17578888.001]
  • [Cites] J Appl Physiol (1985). 2005 Apr;98(4):1154-62 [15772055.001]
  • [Cites] Metabolism. 2009 Jul;58(7):946-53 [19409578.001]
  • [Cites] J Nutr. 2009 Dec;139(12):2365-72 [19864399.001]
  • [Cites] Science. 2001 Aug 31;293(5535):1673-7 [11533494.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Apr;94(4):1393-400 [19174496.001]
  • [Cites] Circulation. 2009 Oct 20;120(16):1640-5 [19805654.001]
  • [Cites] Diabetes. 2009 Oct;58(10 ):2246-57 [19592618.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1178-88 [15251865.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1796-808 [14679176.001]
  • [Cites] J Lipid Res. 2008 Feb;49(2):308-23 [17986714.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1793-801 [16823477.001]
  • [Cites] Biochem Pharmacol. 2009 Jun 15;77(12):1835-44 [19428338.001]
  • [Cites] J Endocrinol. 2008 Jul;198(1):169-74 [18577571.001]
  • [Cites] Circulation. 2000 Sep 12;102(11):1296-301 [10982546.001]
  • [Cites] Endocrine. 2006 Feb;29(1):109-17 [16622298.001]
  • [Cites] Circulation. 2008 Feb 12;117(6):806-15 [18227385.001]
  • [Cites] J Intern Med. 2007 Oct;262(4):415-21 [17875177.001]
  • [Cites] Int J Vitam Nutr Res. 2009 Jan;79(1):14-23 [19838999.001]
  • [Cites] Genome Biol. 2008 Jan 21;9(1):R14 [18208606.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):563-70 [19176282.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2009 Jul;19(6):440-9 [19346117.001]
  • [Cites] J Clin Epidemiol. 1991;44(2):183-90 [1995775.001]
  • [Cites] J Am Diet Assoc. 2004 Jan;104(1):86-9 [14702589.001]
  • [Cites] Diabetes Metab. 2009 Sep;35(4):251-60 [19539513.001]
  • [Cites] Regul Pept. 2009 Apr 10;154(1-3):102-6 [19233230.001]
  • [Cites] Life Sci. 2009 Aug 26;85(9-10):357-64 [19631668.001]
  • [Cites] Thromb Res. 2007;119(1):79-84 [16476470.001]
  • (PMID = 20424938.001).
  • [ISSN] 1534-3111
  • [Journal-full-title] Current hypertension reports
  • [ISO-abbreviation] Curr. Hypertens. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / Adiponectin; 0 / Cytokines; 0 / Interleukins; 0 / Leptin; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 2ZD004190S / Threonine; 452VLY9402 / Serine; 9007-41-4 / C-Reactive Protein
  • [Number-of-references] 49
  •  go-up   go-down


77. Konturek PC, Burnat G, Rau T, Hahn EG, Konturek S: Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci; 2008 Mar;53(3):597-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the role of adiponectin (anti-inflammatory adipokine from adipose tissue) and ghrelin (orexigenic peptide gastric origin) on the progression of Barrett's carcinogenesis has not been investigated so far.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis / physiology. Barrett Esophagus / metabolism. Esophageal Neoplasms / metabolism. Receptors, Adiponectin / metabolism. Receptors, Ghrelin / metabolism
  • [MeSH-minor] Adiponectin / metabolism. Cell Line, Tumor. Culture Media. Cyclooxygenase 2 / metabolism. Deoxycholic Acid. Epithelium / metabolism. Ghrelin / metabolism. Humans. Hydrogen-Ion Concentration. Interleukin-1beta / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aliment Pharmacol Ther. 2005 Nov 15;22(10):1005-10 [16268976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81 [14983034.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):466-72 [15701829.001]
  • [Cites] FASEB J. 2004 Mar;18(3):439-56 [15003990.001]
  • [Cites] Eur J Endocrinol. 2005 Sep;153(3):403-7 [16131603.001]
  • [Cites] Am J Gastroenterol. 2001 Feb;96(2):331-7 [11232672.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 23;345(1):271-9 [16678125.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):4255-61 [11089560.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Oct;319(1):477-87 [16868036.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Feb;2(2):80-8 [16932262.001]
  • [Cites] Regul Pept. 2006 May 15;134(2-3):105-13 [16529829.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Apr;92(4):1510-6 [17213279.001]
  • [Cites] Circulation. 2004 May 11;109(18):2221-6 [15117840.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1623-30 [12023994.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):18341-7 [15734737.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Curr Opin Gastroenterol. 2002 Jul;18(4):471-8 [17033323.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3642-6 [15897559.001]
  • [Cites] Curr Atheroscler Rep. 2006 Sep;8(5):433-8 [16901415.001]
  • [Cites] Clin Sci (Lond). 2006 Mar;110(3):267-78 [16464169.001]
  • [Cites] J Clin Invest. 2004 Jul;114(1):57-66 [15232612.001]
  • [Cites] Endocr Rev. 2006 Dec;27(7):762-78 [17056740.001]
  • [Cites] Eur J Pharmacol. 2006 Apr 24;536(1-2):171-81 [16581065.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2376-81 [16639730.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1784-92 [16823476.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i1-5 [15711002.001]
  • (PMID = 17763959.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Culture Media; 0 / Ghrelin; 0 / Interleukin-1beta; 0 / Receptors, Adiponectin; 0 / Receptors, Ghrelin; 0 / Tumor Necrosis Factor-alpha; 005990WHZZ / Deoxycholic Acid; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


78. Winkler G, Cseh K: [Molecular mechanisms and correlations of insulin resistance, obesity, and type 2 diabetes mellitus]. Orv Hetil; 2009 Apr 26;150(17):771-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adipose tissue cells express and secrete numerous proteins influencing the signal transduction pathways of insulin receptor by auto-, para- and endocrine manner.
  • Several cytokines, tumor necrosis factor-alpha and its soluble receptor forms, sTNFR1 and sTNFR2, resistin, retinol-binding protein 4, plasminogen activator inhibitor, lipocain 1 inhibit the signalization of insulin receptor causing insulin resistance in target tissues, mainly in adipose, liver and muscle, brain, endothelial as well as in pancreatic beta-cells.
  • However, many other proteins produced by the fat tissue, such as adiponectin, visfatin, vaspin, apelin, omentin and chemerin enhance the signal transmission of the receptor.
  • [MeSH-minor] Animals. Humans. Leptin / metabolism. Lipocalin 1 / metabolism. Mutation. Plasminogen Inactivators / metabolism. Resistin / metabolism. Retinol-Binding Proteins, Plasma / metabolism. Transcription, Genetic. Tumor Necrosis Factor-alpha / metabolism


79. Changizi V, Kheradmand AA, Oghabian MA: Application of small-angle X-ray scattering for differentiation among breast tumors. J Med Phys; 2008 Jan;33(1):19-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of small-angle X-ray scattering for differentiation among breast tumors.
  • As breast cancer is the most widespread cancer in women and differentiation among its tumors is important, this project compared the results of coherent X-ray scattering measurements obtained from benign and malignant breast tissues.
  • One hundred thirty-one breast-tissue samples, including normal, fibrocystic changes and carcinoma, were studied at the 6 degrees scattering angle.
  • These profiles showed a few peak positions for adipose (1.15 +/- 0.06 nm(-1)), mixed normal (1.15 +/- 0.06 nm(-1) and 1.4 +/- 0.04 nm(-1)), fibrocystic changes (1.46 +/- 0.05 nm(-1) and 1.74 +/- 0.04 nm(-1)) and carcinoma (1.55 +/- 0.04 nm(-1), 1.73 +/- 0.06 nm(-1), 1.85 +/- 0.05 nm(-1)).
  • We were able to differentiate between normal, fibrocystic changes (benign) and carcinoma (malignant) breast tissues by SAXS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Dec 1;80(11):2091-9 [9392331.001]
  • [Cites] Phys Med Biol. 1982 Apr;27(4):463-99 [7045898.001]
  • [Cites] Am J Epidemiol. 1980 Mar;111(3):301-8 [7361754.001]
  • [Cites] Am J Prev Med. 1998 Feb;14(2):143-53 [9631167.001]
  • [Cites] Phys Med Biol. 1999 Jul;44(7):1791-802 [10442713.001]
  • [Cites] Int J Med Sci. 2005;2(3):118-21 [16007264.001]
  • (PMID = 20041048.001).
  • [ISSN] 1998-3913
  • [Journal-full-title] Journal of medical physics
  • [ISO-abbreviation] J Med Phys
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2786093
  • [Keywords] NOTNLM ; Breast tumor / coherent scattering / small-angle X-ray scattering
  •  go-up   go-down


80. Pandzić Jaksić V: [Adipocytokines as mediators of metabolic role of adipose tissue]. Acta Med Croatica; 2010 Oct;64(4):253-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adipocytokines as mediators of metabolic role of adipose tissue].
  • The discovery of adipocytokines, products of adipose tissue, has been a turning point in the understanding of metabolic disorders.
  • Historically considered as a passive depot of energy, adipose tissue has become an important active participant and adipocytokines crucial mediators of its metabolic role.
  • Among a number of adipose tissue products, leptin and adiponectin are exclusively secreted by adipocytes.
  • Recent investigations have also emphasized the important role of resistin, visfatin, retinol binding protein 4, and of a whole list of cytokines like interleukin-6, tumor necrosis factor a, plasminogen activator inhibitor-1, or a chemokine, monocyte chemoattractant protein-1.
  • The fact that secretory balance of adipose tissue in obesity is shifted towards the proinflammatory spectrum has supported the hypothesis on the development of dysfunctional adipose tissue in these circumstances.
  • [MeSH-major] Adipokines / physiology. Adipose Tissue / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21688608.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Adipokines
  •  go-up   go-down


81. Cousin B, Ravet E, Poglio S, De Toni F, Bertuzzi M, Lulka H, Touil I, André M, Grolleau JL, Péron JM, Chavoin JP, Bourin P, Pénicaud L, Casteilla L, Buscail L, Cordelier P: Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. PLoS One; 2009;4(7):e6278
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo.
  • BACKGROUND: Normal tissue homeostasis is maintained by dynamic interactions between epithelial cells and their microenvironment.
  • Indeed, aberrant stromal-epithelial interactions contribute to pancreatic ductal adenocarcinoma (PDAC) spread and metastasis, and this raises the possibility that novel stroma-targeted therapies represent additional approaches for combating this malignant disease.
  • The aim of the present study was to determine the effect of human stromal cells derived from adipose tissue (ADSC) on pancreatic tumor cell proliferation.
  • PRINCIPAL FINDINGS: Co-culturing pancreatic tumor cells with ADSC and ADSC-conditioned medium sampled from different donors inhibited cancer cell viability and proliferation.
  • In vivo, a single intra-tumoral injection of ADSC in a model of pancreatic adenocarcinoma induced a strong and long-lasting inhibition of tumor growth.
  • CONCLUSION: These data indicate that ADSC strongly inhibit PDAC proliferation, both in vitro and in vivo and induce tumor cell death by altering cell cycle progression.
  • [MeSH-major] Adenocarcinoma / pathology. Adipose Tissue / cytology. Cell Death. Pancreatic Neoplasms / pathology. Stromal Cells / cytology
  • [MeSH-minor] Adult. Cell Line, Tumor. Cell Proliferation. Coculture Techniques. Culture Media, Conditioned. G1 Phase. Humans


82. Taxonera C, Schwartz DA, García-Olmo D: Emerging treatments for complex perianal fistula in Crohn's disease. World J Gastroenterol; 2009 Sep 14;15(34):4263-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging treatments for complex perianal fistula in Crohn's disease.
  • Correct diagnosis, characterization and classification of the fistulas are essential to optimize treatment.
  • Nevertheless, in the case of patients whose fistulas are associated with Crohn's disease, complete closure is particularly difficult to achieve.
  • Systemic medical treatments (antibiotics, thiopurines and other immunomodulatory agents, and, more recently, anti-tumor necrosis factor-alpha agents such as infliximab) have been tried with varying degrees of success.
  • This review will focus on emerging novel treatments for perianal disease in Crohn's patients.
  • These include locally applied infliximab or tacrolimus, fistula plugs, instillation of fibrin glue and the use of adult expanded adipose-derived stem cell injection.
  • [MeSH-major] Crohn Disease / complications. Rectal Fistula / therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Anti-Bacterial Agents / therapeutic use. Azathioprine / therapeutic use. Humans. Immunologic Factors / therapeutic use. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1569-73 [16998638.001]
  • [Cites] Dis Colon Rectum. 2006 Dec;49(12):1837-41 [17041753.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18 [17269996.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Mar 1;25(5):557-67 [17305756.001]
  • [Cites] Inflamm Bowel Dis. 2007 Mar;13(3):245-53 [17206671.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Aug 1;26(3):421-30 [17635377.001]
  • [Cites] Int J Colorectal Dis. 2008 Mar;23(3):319-24 [18038233.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):838-43 [18330649.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1721-9 [18616656.001]
  • [Cites] Am J Gastroenterol. 2008 Oct;103(10):2527-35 [18684178.001]
  • [Cites] Inflamm Bowel Dis. 2009 Jan;15(1):17-24 [18668682.001]
  • [Cites] Dis Colon Rectum. 2009 Jan;52(1):79-86 [19273960.001]
  • [Cites] Gut. 2009 Jul;58(7):940-8 [19201775.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1503-7 [14598267.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1508-30 [14598268.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Dec;18(11-12):1113-20 [14653831.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):19-31 [14699483.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 15;19(4):427-34 [14871282.001]
  • [Cites] N Engl J Med. 2004 Feb 26;350(9):876-85 [14985485.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):432-6 [14978618.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Sep;16(9):921-6 [15316419.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):308-19 [15335361.001]
  • [Cites] Br J Surg. 1976 Jan;63(1):1-12 [1267867.001]
  • [Cites] N Engl J Med. 1980 May 1;302(18):981-7 [6102739.001]
  • [Cites] Inflamm Bowel Dis. 1999 Nov;5(4):239-45 [10579116.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1271-7 [10579967.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):337-40 [10587195.001]
  • [Cites] Abdom Imaging. 2000 Jan-Feb;25(1):67-74 [10652926.001]
  • [Cites] J Clin Gastroenterol. 2000 Mar;30(2):200-2 [10730928.001]
  • [Cites] Dis Colon Rectum. 2000 Jul;43(7):944-9; discussion 949-50 [10910240.001]
  • [Cites] Gut. 2000 Sep;47(3):436-40 [10940284.001]
  • [Cites] Radiology. 2001 Jan;218(1):75-84 [11152782.001]
  • [Cites] Tissue Eng. 2001 Apr;7(2):211-28 [11304456.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1064-72 [11677197.001]
  • [Cites] Int J Colorectal Dis. 2001 Sep;16(5):292-7 [11686526.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):875-80 [11910338.001]
  • [Cites] Dis Colon Rectum. 2002 Dec;45(12):1608-15 [12473883.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):332-9 [12591051.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):498-502 [12682544.001]
  • [Cites] Inflamm Bowel Dis. 2003 Mar;9(2):98-103 [12769443.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):577-83 [12792431.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):584-9 [12792432.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):380-8 [12891539.001]
  • [Cites] Int J Colorectal Dis. 2003 Sep;18(5):451-4 [12756590.001]
  • [Cites] Can J Gastroenterol. 2003 Sep;17(9):555-8 [14532930.001]
  • [Cites] Gastroenterology. 1980 Aug;79(2):357-65 [7399243.001]
  • [Cites] Gut. 1980 Jun;21(6):525-7 [7429313.001]
  • [Cites] Gastroenterology. 1982 Aug;83(2):383-7 [7084615.001]
  • [Cites] Am J Gastroenterol. 1984 Jul;79(7):533-40 [6741906.001]
  • [Cites] Gut. 1990 Oct;31(10):1133-7 [2083858.001]
  • [Cites] Dis Colon Rectum. 1992 Oct;35(10):928-32 [1395978.001]
  • [Cites] Int J Colorectal Dis. 1992 Dec;7(4):214-8 [1293243.001]
  • [Cites] Dis Colon Rectum. 1993 May;36(5):447-9 [8482163.001]
  • [Cites] J Clin Gastroenterol. 1995 Jan;20(1):27-32 [7884173.001]
  • [Cites] Ann Intern Med. 1995 Jul 15;123(2):132-42 [7778826.001]
  • [Cites] N Engl J Med. 1997 Sep 18;337(12):816-21 [9295241.001]
  • [Cites] Am J Gastroenterol. 1998 Dec;93(12):2529-32 [9860419.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):318-21 [10022622.001]
  • [Cites] N Engl J Med. 1999 May 6;340(18):1398-405 [10228190.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Dec;20(11-12):1329-36 [15606395.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Feb 15;21(4):391-400 [15709989.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):164-8 [15720356.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):862-9 [15825070.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):758-67 [15750797.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):768-74 [15768185.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):799-808 [15785883.001]
  • [Cites] N Engl J Med. 2005 May 26;352(21):2193-201 [15917384.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1416-23 [15933795.001]
  • [Cites] Inflamm Bowel Dis. 2005 Aug;11(8):727-32 [16043987.001]
  • [Cites] Colorectal Dis. 2005 Sep;7(5):513-8 [16108891.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Dec;22(11-12):1107-13 [16305724.001]
  • [Cites] Gut. 2006 Mar;55 Suppl 1:i36-58 [16481630.001]
  • [Cites] Am J Surg. 2006 Mar;191(3):424-7 [16490560.001]
  • [Cites] Dis Colon Rectum. 2006 Mar;49(3):371-6 [16421664.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Apr 15;23(8):1127-36 [16611273.001]
  • [Cites] Scand J Gastroenterol. 2006 Sep;41(9):1064-72 [16938720.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Sep;4(9):1130-4 [16905369.001]
  • (PMID = 19750568.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Immunologic Factors; 0 / Tumor Necrosis Factor-alpha; E7WED276I5 / 6-Mercaptopurine; MRK240IY2L / Azathioprine
  • [Number-of-references] 84
  • [Other-IDs] NLM/ PMC2744181
  •  go-up   go-down


83. Murosaki S, Lee TR, Muroyama K, Shin ES, Cho SY, Yamamoto Y, Lee SJ: A combination of caffeine, arginine, soy isoflavones, and L-carnitine enhances both lipolysis and fatty acid oxidation in 3T3-L1 and HepG2 cells in vitro and in KK mice in vivo. J Nutr; 2007 Oct;137(10):2252-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of caffeine, arginine, soy isoflavones, and L-carnitine enhances both lipolysis and fatty acid oxidation in 3T3-L1 and HepG2 cells in vitro and in KK mice in vivo.
  • To develop an anti-obesity agent containing dietary components, we focused on the mechanisms that enhance both lipolysis and fatty acid oxidation.
  • Soy isoflavones and L-carnitine (SL), stimulators of carnitine palmitoyl transferase 1A and a cofactor for beta-oxidation of fatty acids, respectively, were used to enhance fatty acid oxidation.
  • Effects of a combination of CA and SL (CASL) on lipid metabolism were studied in vitro and in vivo.
  • During 3T3-L1 differentiation, lipid accumulation was significantly lower in cells treated with CASL (50 micromol/L, 1 mmol/L, 1 micromol/L, and 1 mmol/L, respectively) compared with each alone.
  • In addition, after obese KK mice were fed a low-fat diet for 2 wk, adipose tissue weights were significantly lower in those fed CASL, but not CA or SL alone, compared with the control mice.
  • [MeSH-minor] 3T3-L1 Cells. Animals. Anti-Obesity Agents / administration & dosage. Anti-Obesity Agents / pharmacology. Cell Line, Tumor. Drug Combinations. Fatty Acids / metabolism. Food Deprivation. Humans. Mice. Oxidation-Reduction / drug effects

  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. L-CARNITINE .
  • Hazardous Substances Data Bank. CAFFEINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885007.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Obesity Agents; 0 / Drug Combinations; 0 / Fatty Acids; 0 / Isoflavones; 3G6A5W338E / Caffeine; 94ZLA3W45F / Arginine; S7UI8SM58A / Carnitine
  •  go-up   go-down


84. Kim JA, Yeh DC, Ver M, Li Y, Carranza A, Conrads TP, Veenstra TD, Harrington MA, Quon MJ: Phosphorylation of Ser24 in the pleckstrin homology domain of insulin receptor substrate-1 by Mouse Pelle-like kinase/interleukin-1 receptor-associated kinase: cross-talk between inflammatory signaling and insulin signaling that may contribute to insulin resistance. J Biol Chem; 2005 Jun 17;280(24):23173-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Wild-type mPLK, but not a kinase-inactive mutant (mPLK-KD), directly phosphorylated full-length IRS-1 in vitro.
  • This in vitro phosphorylation was increased when mPLK was immunoprecipitated from tumor necrosis factor (TNF)-alpha-treated cells.
  • In NIH-3T3(IR) cells, wild-type mPLK (but not mPLK-KD) co-immunoprecipitated with IRS-1.
  • IRS-1-S24D also had an impaired ability to mediate insulin-stimulated translocation of GLUT4 in rat adipose cells.
  • Importantly, endogenous mPLK/IRAK was activated in response to TNF-alpha or interleukin 1 treatment of primary adipose cells.
  • [MeSH-minor] Adipose Tissue / cytology. Animals. Blood Proteins / chemistry. COS Cells. Cell Line. Glucose Transporter Type 4. Glutathione Transferase / metabolism. Humans. Immunoblotting. Immunoprecipitation. Inflammation. Insulin / metabolism. Insulin Receptor Substrate Proteins. Interleukin-1 / metabolism. Interleukin-1 Receptor-Associated Kinases. Mass Spectrometry. Mice. Models, Molecular. Monosaccharide Transport Proteins / metabolism. Muscle Proteins / metabolism. Mutation. NIH 3T3 Cells. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation. Plasmids / metabolism. Protein Binding. Protein Structure, Tertiary. Protein Transport. Rats. Recombinant Fusion Proteins / chemistry. Signal Transduction. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Substrate Specificity. Transfection. Tumor Necrosis Factor-alpha / metabolism

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. L-SERINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849359.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01-CA-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Glucose Transporter Type 4; 0 / IRS1 protein, human; 0 / Insulin; 0 / Insulin Receptor Substrate Proteins; 0 / Interleukin-1; 0 / Irs1 protein, mouse; 0 / Irs1 protein, rat; 0 / Monosaccharide Transport Proteins; 0 / Muscle Proteins; 0 / Phosphoproteins; 0 / Recombinant Fusion Proteins; 0 / SLC2A4 protein, human; 0 / Slc2a4 protein, mouse; 0 / Slc2a4 protein, rat; 0 / Tumor Necrosis Factor-alpha; 0 / platelet protein P47; 452VLY9402 / Serine; EC 2.5.1.18 / Glutathione Transferase; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Interleukin-1 Receptor-Associated Kinases; EC 2.7.11.1 / Irak1 protein, mouse; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


85. Mohapatra J, Sharma M, Singh S, Pandya G, Chatterjee A, Balaraman R, Patel PR, Jain MR: Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice. J Pharm Pharmacol; 2009 Nov;61(11):1493-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the precise role of adipokines in the insulin-sensitising effects of the CB1 antagonist rimonabant is not clear.
  • The expression of different adipokines in white adipose tissue was analysed by quantitative real-time PCR.
  • Gene expression analysis indicated that tumour necrosis factor-alpha, visfatin and retinol binding protein-4 were downregulated in the adipose tissue of ob/ob mice treated with rimonabant compared with controls, whereas adiponectin was significantly upregulated.
  • CONCLUSIONS: Rimonabant-mediated alteration of adipokines in white adipose tissues may play a role in improving insulin sensitivity in obese animals.
  • [MeSH-major] Adipokines / physiology. Adipose Tissue, White / drug effects. Anti-Obesity Agents / therapeutic use. Glucose Intolerance / drug therapy. Insulin Resistance. Obesity / drug therapy. Piperidines / therapeutic use. Pyrazoles / therapeutic use
  • [MeSH-minor] Adiponectin / blood. Adipose Tissue / drug effects. Animals. Blood Glucose / metabolism. Body Weight / drug effects. Down-Regulation. Female. Gene Expression. Glucose Tolerance Test. Insulin / blood. Leptin / deficiency. Mice. Mice, Knockout. Models, Animal. Nicotinamide Phosphoribosyltransferase / genetics. Nicotinamide Phosphoribosyltransferase / metabolism. Organ Size / drug effects. RNA, Messenger / metabolism. Receptor, Cannabinoid, CB1 / antagonists & inhibitors. Retinol-Binding Proteins, Plasma / genetics. Retinol-Binding Proteins, Plasma / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Obesity.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19903374.001).
  • [ISSN] 2042-7158
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adipokines; 0 / Adiponectin; 0 / Anti-Obesity Agents; 0 / Blood Glucose; 0 / Insulin; 0 / Leptin; 0 / Piperidines; 0 / Pyrazoles; 0 / RNA, Messenger; 0 / Rbp4 protein, mouse; 0 / Receptor, Cannabinoid, CB1; 0 / Retinol-Binding Proteins, Plasma; 0 / Tumor Necrosis Factor-alpha; 158681-13-1 / rimonabant; EC 2.4.2.12 / Nicotinamide Phosphoribosyltransferase
  •  go-up   go-down


86. Gilardini L, Zulian A, Girola A, Redaelli G, Conti A, Invitti C: Predictors of the early impairment of renal disease in human obesity. Int J Obes (Lond); 2010 Feb;34(2):287-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of the early impairment of renal disease in human obesity.
  • We therefore investigated (1) the predictors of AER after 3 months of lifestyle intervention in a large cohort of nondiabetic obese women and (2) the relationships between AER and the adipose tissue gene expression of adipokines linked to inflammation and insulin resistance.
  • At baseline, in a subgroup of 34 women, subcutaneous adipose tissue biopsy was carried out for the analysis of mRNA expression levels of adiponectin, suppressor of cytokine signaling 3 (SOCS-3), tumor necrosis factor alpha (TNF-alpha), pentraxine 3 (PTX-3), angiotensinogen and angiotensin-converting enzyme, and a blood sample was also taken from this group for the measurement of circulating adiponectin, interleukin-6, TNF-alpha and PTX-3.
  • At baseline, higher AER was associated to significantly higher adipose tissue mRNA expression levels of SOCS-3 and PTX-3 (P<0.05) and to higher TNF-alpha and angiotensinogen expression.
  • CONCLUSIONS: In obese women, weight loss alone is not sufficient to induce the AER decrease that occurs only with a concomitant improvement in glucose homeostasis.
  • The adipose tissue gene expression profile seems to favor the early renal impairment often seen in obese subjects.
  • [MeSH-minor] Adiponectin / metabolism. Albumins / secretion. Albuminuria / urine. Angiotensinogen / metabolism. Body Mass Index. C-Reactive Protein / metabolism. Female. Gene Expression / genetics. Humans. Middle Aged. Peptidyl-Dipeptidase A / metabolism. Predictive Value of Tests. Risk Reduction Behavior. Serum Amyloid P-Component / metabolism. Subcutaneous Fat / metabolism. Suppressor of Cytokine Signaling Proteins / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Weight Control.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859076.001).
  • [ISSN] 1476-5497
  • [Journal-full-title] International journal of obesity (2005)
  • [ISO-abbreviation] Int J Obes (Lond)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Albumins; 0 / SOCS3 protein, human; 0 / Serum Amyloid P-Component; 0 / Suppressor of Cytokine Signaling Proteins; 0 / Tumor Necrosis Factor-alpha; 11002-13-4 / Angiotensinogen; 148591-49-5 / PTX3 protein; 9007-41-4 / C-Reactive Protein; EC 3.4.15.1 / Peptidyl-Dipeptidase A
  •  go-up   go-down


87. Patsouris D, Neels JG, Fan W, Li PP, Nguyen MT, Olefsky JM: Glucocorticoids and thiazolidinediones interfere with adipocyte-mediated macrophage chemotaxis and recruitment. J Biol Chem; 2009 Nov 06;284(45):31223-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The link between intra-abdominal adiposity and type II diabetes has been known for decades, and adipose tissue macrophage (ATM)-associated inflammation has recently been linked to insulin resistance.
  • We demonstrate that tumor necrosis factor alpha and free fatty acids, key inflammatory stimuli involved in obesity-associated autocrine/paracrine inflammatory signaling, stimulate adipocyte expression and secretion of macrophage chemoattractants.
  • Overall, our results elucidate a beneficial function of peroxisome proliferator-activated receptor gamma activation and glucocorticoid receptor/glucocorticoids in adipose tissue and indicate that pharmacologic prevention of ATM accumulation could be beneficial.
  • [MeSH-minor] Animals. Cell Line. Fatty Acids, Nonesterified / immunology. Male. Mice. Mice, Inbred C57BL. Tumor Necrosis Factor-alpha / immunology

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2001 Dec 17;20(24):7108-16 [11742987.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2166-70 [11739957.001]
  • [Cites] Diabetes. 2002 Aug;51(8):2426-33 [12145154.001]
  • [Cites] Diabetes Obes Metab. 2003 Jan;5(1):5-12 [12542720.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Mar 26;107(1):62-7 [12593897.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 23;305(1):122-8 [12732205.001]
  • [Cites] Nitric Oxide. 2004 Feb;10(1):36-41 [15050533.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):43273-84 [15292195.001]
  • [Cites] Clin Sci (Lond). 1999 May;96(5):513-23 [10209084.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] Genes Dev. 2005 Aug 1;19(15):1737-42 [16077002.001]
  • [Cites] Obes Res. 2005 Jul;13(7):1131-3 [16076979.001]
  • [Cites] J Immunol. 2005 Sep 15;175(6):3737-45 [16148119.001]
  • [Cites] Nature. 2005 Sep 29;437(7059):759-63 [16127449.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35361-71 [16085647.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):33-5 [16395402.001]
  • [Cites] Nat Rev Immunol. 2006 Jan;6(1):44-55 [16493426.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):571-80 [16511589.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):590-7 [16511591.001]
  • [Cites] J Biol Chem. 2006 Sep 8;281(36):26602-14 [16809344.001]
  • [Cites] Diabetologia. 2006 Oct;49(10):2350-8 [16896941.001]
  • [Cites] Obesity (Silver Spring). 2006 Aug;14(8):1353-62 [16988077.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):175-84 [17200717.001]
  • [Cites] Nat Rev Immunol. 2007 Mar;7(3):202-12 [17318231.001]
  • [Cites] Circulation. 2007 Feb 27;115(8):1029-38 [17296858.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jun;92(6):2240-7 [17374712.001]
  • [Cites] FASEB J. 2007 Jul;21(9):2185-94 [17384139.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E219-27 [17389706.001]
  • [Cites] Diabetes. 2007 Sep;56(9):2242-50 [17473219.001]
  • [Cites] Cell Metab. 2007 Nov;6(5):386-97 [17983584.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):35279-92 [17916553.001]
  • [Cites] FEBS Lett. 2008 Jan 9;582(1):97-105 [18053812.001]
  • [Cites] Endocrinology. 2008 May;149(5):2584-91 [18218694.001]
  • [Cites] J Endocrinol. 2008 May;197(2):189-204 [18434349.001]
  • [Cites] Diabetes. 2008 May;57(5):1254-61 [18268047.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2008 May;294(5):E898-909 [18303122.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):2992-3002 [18769626.001]
  • [Cites] Cell Metab. 2008 Oct;8(4):301-9 [18840360.001]
  • [Cites] Diabetes. 2009 Jan;58(1):104-15 [18835938.001]
  • [Cites] Mol Cell Biol. 2009 Mar;29(5):1363-74 [19103747.001]
  • [Cites] Eur J Immunol. 2009 Mar;39(3):894-901 [19197940.001]
  • [Cites] Cell Metab. 2009 Apr;9(4):339-49 [19356715.001]
  • [Cites] J Biol Chem. 2009 Jul 31;284(31):20692-8 [19494115.001]
  • [Cites] Nat Med. 2009 Aug;15(8):930-9 [19633656.001]
  • [Cites] Nat Med. 2009 Aug;15(8):921-9 [19633657.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):12629-35 [11278270.001]
  • [Cites] Nat Immunol. 2001 Feb;2(2):108-15 [11175802.001]
  • [Cites] Nat Med. 2009 Aug;15(8):914-20 [19633658.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):437-46 [11489937.001]
  • [Cites] J Clin Invest. 2002 May;109(10):1321-6 [12021247.001]
  • (PMID = 19740750.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK033651; United States / NIDDK NIH HHS / DK / P01 DK074868; United States / NIDDK NIH HHS / DK / R01 DK033651; United States / NICHD NIH HHS / HD / U54 HD 012303-25; United States / NIDDK NIH HHS / DK / T32 DK007494; United States / NIDDK NIH HHS / DK / DK074868; United States / NICHD NIH HHS / HD / P50 HD012303; United States / NICHD NIH HHS / HD / U54 HD012303; United States / NIDDK NIH HHS / DK / R37 DK033651
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids, Nonesterified; 0 / Glucocorticoids; 0 / Thiazolidinediones; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2781521
  •  go-up   go-down


88. Barbarroja N, López-Pedrera R, Mayas MD, García-Fuentes E, Garrido-Sánchez L, Macías-González M, El Bekay R, Vidal-Puig A, Tinahones FJ: The obese healthy paradox: is inflammation the answer? Biochem J; 2010 Aug 15;430(1):141-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A paradoxical but common finding in the obesity clinic is the identification of individuals who can be considered 'inappropriately' healthy for their degree of obesity.
  • We think that studying these obese but metabolically healthy individuals and comparing them with equally obese but insulin-resistant individuals could provide important insights into the mechanistic link between adipose tissue expansion and associated metabolic alterations.
  • In the present study, we investigated whether there are differences in inflammatory and insulin signalling pathways in VAT (visceral adipose tissue) that could account for the metabolic differences exhibited by morbidly obese individuals who are either insulin-resistant (IR-MO) or paradoxically insulin-sensitive (NIR-MO).
  • For instance, all morbidly obese patients, irrespective of their insulin resistance, showed increased expression of TNFalpha (tumour necrosis factor alpha) and activation of JNK1/2 (c-Jun N-terminal kinase 1/2).
  • [MeSH-minor] Adult. Biomarkers / metabolism. Female. Humans. I-kappa B Proteins / biosynthesis. I-kappa B Proteins / genetics. Inflammation / immunology. Inflammation / metabolism. Insulin / physiology. Insulin Receptor Substrate Proteins / biosynthesis. Insulin Receptor Substrate Proteins / genetics. Insulin Resistance. Interleukin-1beta / biosynthesis. Interleukin-1beta / genetics. Interleukin-6 / biosynthesis. Interleukin-6 / genetics. Intra-Abdominal Fat / immunology. Intra-Abdominal Fat / metabolism. Macrophages / immunology. Male. Middle Aged. Mitogen-Activated Protein Kinases / biosynthesis. Mitogen-Activated Protein Kinases / genetics. NF-KappaB Inhibitor alpha. NF-kappa B / biosynthesis. NF-kappa B / genetics. Proto-Oncogene Proteins c-akt / biosynthesis. Proto-Oncogene Proteins c-akt / genetics. RNA, Messenger / biosynthesis. Tumor Necrosis Factor-alpha / biosynthesis. Tumor Necrosis Factor-alpha / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Biochem J. 2010 Sep 1;430(2):e1-4 [20704568.001]
  • (PMID = 20522023.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0802051
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / I-kappa B Proteins; 0 / IRS1 protein, human; 0 / Insulin; 0 / Insulin Receptor Substrate Proteins; 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / NF-kappa B; 0 / NFKBIA protein, human; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 139874-52-5 / NF-KappaB Inhibitor alpha; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


89. Krishnan AV, Swami S, Feldman D: Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol; 2010 Jul;121(1-2):343-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcitriol (1,25-dihydroxyvitamin D3), the hormonally active metabolite of vitamin D, inhibits the growth and induces the differentiation of many malignant cells including breast cancer (BCa) cells.
  • Calcitriol also inhibits invasion, metastasis and tumor angiogenesis in experimental models of BCa.
  • Calcitriol decreases the expression of aromatase, the enzyme that catalyzes estrogen synthesis selectively in BCa cells and the breast adipose tissue surrounding BCa, by a direct repression of aromatase transcription via promoter II as well as an indirect effect due to the reduction in the levels and biological activity of PGE2, which is a major stimulator of aromatase transcription through promoter II in BCa.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20156557.001).
  • [ISSN] 1879-1220
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA130991; United States / NCI NIH HHS / CA / CA130991
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Estrogens; 1406-16-2 / Vitamin D; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases; EC 1.1.1.141 / 15-hydroxyprostaglandin dehydrogenase; EC 1.14.99.1 / Cyclooxygenase 2; FXC9231JVH / Calcitriol
  • [Number-of-references] 76
  •  go-up   go-down


90. Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD, EURODIAB Prospective Complications Study Group: Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab; 2006 Jan;91(1):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Adipose tissue is a source of several adipocytokines that may contribute to vascular complications.
  • RESULTS: We found that adiponectin was negatively correlated with body mass index, waist to hip ratio, insulin, and fasting triglyceride, and positively with high-density lipoprotein, low-density lipoprotein, and total cholesterol, TNF-alpha, and sVCAM-1, but was not related to C-reactive protein, IL-6, and sE-selectin.
  • The association between adiponectin and albuminuria was attenuated by GFR, whereas the association of adiponectin with retinopathy and cardiovascular disease disappeared after adjustments for established risk factors.
  • [MeSH-minor] Adolescent. Adult. Albuminuria / metabolism. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Blood Pressure / physiology. Cardiovascular Diseases / epidemiology. Creatinine / blood. Diabetic Angiopathies / blood. Diabetic Angiopathies / physiopathology. Diabetic Retinopathy / physiopathology. Female. Glomerular Filtration Rate. Hemoglobin A, Glycosylated / metabolism. Humans. Kidney Function Tests. Male. Middle Aged. Risk Factors. Tumor Necrosis Factor-alpha / metabolism. Vascular Cell Adhesion Molecule-1 / metabolism

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • MedlinePlus Health Information. consumer health - Diabetic Kidney Problems.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219717.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Hemoglobin A, Glycosylated; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Cell Adhesion Molecule-1; AYI8EX34EU / Creatinine
  •  go-up   go-down


91. Poon E, Verhaegen F: Sci-Sat AM(2): Brachy-08: Monte Carlo calculations of 192Ir high dose rate brachytherapy treatment plans using CT and cone beam CT images. Med Phys; 2008 Jul;35(7Part3):3417
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the effects of tissue heterogeneities and finite patient dimensions for 192Ir high dose rate treatment, CT-based MC calculations for breast and head and neck cases were first performed using the PTRAN_CT photon transport code.
  • Muscles and adipose tissues, which are nearly indistinguishable in CBCT images, are found to cause minimal dose perturbations at 192Ir energies compared to water.
  • The proximity of the tumor to the skin, however, will have an observable impact on the dose up to a few percent.
  • A CBCT-based calculation for an actual treatment plan with the tumor close to the cheek was performed.
  • Since the dose delivered to the tumor is mostly primary dose, deviations are found mostly in the organs at risk where scatter contribution becomes more significant.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512889.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Brachytherapy / Cancer / Computed tomography / Cone beam computed tomography / Dosimetry / Medical image quality / Medical imaging / Monte Carlo methods / Skin / Tissues
  •  go-up   go-down


92. Maiorano E, Capodiferro S, Fanelli B, Calabrese L, Napoli A, Favia G: Hamartomatous angiolipoma of the parotid gland (sialoangiolipoma). Head Neck Pathol; 2008 Mar;2(1):36-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesenchymal tumors of the salivary glands are rare and mostly localized to the parotid gland.
  • We report on the clinico-pathological features of a distinct parotid tumor occurred in a newborn, showing glandular structures admixed with mature lipocytes and blood vessels in variable proportions.
  • The morphological features of the lesion reported herein recapitulate those of sialolipoma but also include the presence of a prominent vascular component intimately admixed with both the glandular and the adipose tissues.
  • [MeSH-major] Angiolipoma / pathology. Hamartoma / pathology. Parotid Gland / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Child, Preschool. Female. Humans. Infant, Newborn

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Mar;36(3):285-6 [10809601.001]
  • [Cites] J Oral Maxillofac Surg. 2000 Jun;58(6):674-7 [10847292.001]
  • [Cites] Ann Diagn Pathol. 2000 Aug;4(4):236-9 [10982301.001]
  • [Cites] Histopathology. 2001 Jan;38(1):30-6 [11135044.001]
  • [Cites] Virchows Arch. 2002 May;440(5):549-50 [12021932.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Feb;32(1):49-53 [12653233.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1986 Sep;65(9):485-91 [3784727.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;411(5):473-8 [2444029.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1987 Nov;14(1):41-4 [3429147.001]
  • [Cites] Laryngoscope. 1988 Aug;98(8 Pt 1):818-21 [3294538.001]
  • [Cites] J Laryngol Otol. 1993 Mar;107(3):257-8 [8509709.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):82-4 [7497449.001]
  • [Cites] J Oral Maxillofac Surg. 1996 Feb;54(2):213-5 [8604073.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jan;86(1):39-45 [8616784.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):242-6 [9071732.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):410-2 [9563794.001]
  • [Cites] J Oral Maxillofac Surg. 1999 Apr;57(4):446-8 [10199497.001]
  • [Cites] Pathol Res Pract. 1999;195(4):247-52 [10337663.001]
  • [Cites] J Oral Pathol Med. 2005 Jan;34(1):59-61 [15610409.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2005 Mar;69(3):429-34 [15733606.001]
  • [Cites] J Craniomaxillofac Surg. 2006 Jan;34(1):43-6 [16343917.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1186-90 [17667541.001]
  • (PMID = 20614340.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807606
  • [Keywords] NOTNLM ; Angiolipoma / Lipoma / Salivary gland neoplasms / Sialolipoma / Soft tissue tumors
  •  go-up   go-down


93. Kazakov DV, Hes O, Hora M, Sima R, Michal M: Primary intranodal cellular angiolipoma. Int J Surg Pathol; 2005 Jan;13(1):99-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiolipoma is a distinct, benign soft tissue tumor that most commonly occurs in young males as multiple small, subcutaneous, tender to painful nodules with predilection for the forearms.
  • Microscopically, the major portion of the lymph node was replaced by mature metaplastic adipose tissue.
  • Lymph nodes are known to be a rare primary site of various tumors usually occurring in other organs.
  • The knowledge of these tumors is important in order not to interpret them as metastatic lesions.
  • The most recognized examples are pigmented nevi, palisading myofibroblastoma, various benign epithelial inclusions, serous cystic tumors of borderline malignancy, and hyperplastic mesothelial inclusions.
  • As we present in this report, angiolipoma is another neoplasm whose primary occurrence in the lymph node should not be misinterpreted as a metastatic tumor or malignant vascular tumor.
  • [MeSH-major] Angiolipoma / pathology. Lymph Nodes / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adipose Tissue / pathology. Aged. Antigens, CD31 / analysis. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Lymphatic Metastasis / diagnosis. Male. Metaplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735863.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor
  •  go-up   go-down


94. Vrieling A, Kampman E: The role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: a review of the literature. Am J Clin Nutr; 2010 Sep;92(3):471-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BMI, physical activity, and nutrition mostly referred to the time at or before diagnosis.
  • Only 10 studies assessed BMI (n = 1), physical activity (n = 4), or nutrition (n = 5) after diagnosis.
  • There may be an association between higher BMI and body fatness before or at the time of diagnosis and a higher all-cause mortality or colorectal cancer-specific mortality or recurrence, although results may differ by sex, tumor location, and molecular subtype.
  • There may be a relation between higher leisure-time physical activity after diagnosis and a lower all-cause or colorectal cancer-specific mortality.
  • [MeSH-major] Body Mass Index. Colorectal Neoplasms. Diet. Exercise. Obesity / complications
  • [MeSH-minor] Adipose Tissue. Cause of Death. Humans. Recurrence. Risk Factors. Survival Rate


95. Yordy JE, Mollenhauer MA, Wilson RM, Wells RS, Hohn A, Sweeney J, Schwacke LH, Rowles TK, Kucklick JR, Peden-Adams MM: Complex contaminant exposure in cetaceans: a comparative E-Screen analysis of bottlenose dolphin blubber and mixtures of four persistent organic pollutants. Environ Toxicol Chem; 2010 Oct;29(10):2143-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These observations do not necessarily provide direct evidence of endocrine disruption; however, they may indicate an environmental source of xenoestrogenic exposure warranting future research.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Environ. Toxicol. Chem. 2010;29:2143-2153. © 2010 SETAC.
  • (PMID = 20872675.001).
  • [ISSN] 1552-8618
  • [Journal-full-title] Environmental toxicology and chemistry
  • [ISO-abbreviation] Environ. Toxicol. Chem.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Water Pollutants, Chemical
  •  go-up   go-down


96. Lu YP, Nolan B, Lou YR, Peng QY, Wagner GC, Conney AH: Voluntary exercise together with oral caffeine markedly stimulates UVB light-induced apoptosis and decreases tissue fat in SKH-1 mice. Proc Natl Acad Sci U S A; 2007 Jul 31;104(31):12936-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Voluntary exercise together with oral caffeine markedly stimulates UVB light-induced apoptosis and decreases tissue fat in SKH-1 mice.
  • Our studies indicate a greater than additive stimulatory effect of combined voluntary exercise and oral administration of a low dose of caffeine on UVB-induced apoptosis.

  • MedlinePlus Health Information. consumer health - Caffeine.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAFFEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):972-8 [10195925.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Mar;83(3):847-50 [9506738.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2187-95 [15598779.001]
  • [Cites] Recent Results Cancer Res. 2005;166:177-211 [15648191.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):275-9 [15668508.001]
  • [Cites] J Appl Physiol (1985). 2005 Apr;98(4):1154-62 [15772055.001]
  • [Cites] J Hepatol. 2005 Apr;42(4):528-34 [15868652.001]
  • [Cites] Arch Intern Med. 2005 May 9;165(9):1005-10 [15883238.001]
  • [Cites] Br J Cancer. 2005 Sep 5;93(5):607-10 [16091758.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1062-7 [16234822.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):103-7 [16032702.001]
  • [Cites] Gut. 2006 Feb;55(2):285-91 [16239255.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1496-500 [16187280.001]
  • [Cites] Melanoma Res. 2006 Feb;16(1):83-7 [16432461.001]
  • [Cites] Epidemiology. 2006 Mar;17(2):124-7 [16477248.001]
  • [Cites] Am J Nurs. 2006 Jan;106(1):40-9, quiz 49-50 [16481779.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 23;345(1):271-9 [16678125.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):279-92 [16728564.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):920-31 [16818856.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] BJOG. 2006 Oct;113(10):1160-6 [16945118.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2108-15 [16699173.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1977-83 [17035408.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2943-7 [17019717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16301-6 [17060638.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):63-9 [17179486.001]
  • [Cites] J Physiol Pharmacol. 2006 Nov;57 Suppl 10:43-51 [17242490.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):401-9 [16912864.001]
  • [Cites] Metabolism. 1999 Oct;48(10):1332-5 [10535400.001]
  • [Cites] Arch Intern Med. 1999 Oct 25;159(19):2290-6 [10547168.001]
  • [Cites] Am J Physiol. 1999 Dec;277(6 Pt 1):E971-5 [10600783.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):128-35 [10639514.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4785-91 [10987287.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S154-5 [10997642.001]
  • [Cites] Trends Endocrinol Metab. 2000 Oct;11(8):327-32 [10996528.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5002-9 [11431333.001]
  • [Cites] Cancer Causes Control. 2001 Sep;12(7):599-606 [11552707.001]
  • [Cites] Proc Nutr Soc. 2001 Aug;60(3):349-56 [11681809.001]
  • [Cites] Nat Med. 2002 Jan;8(1):75-9 [11786910.001]
  • [Cites] Ann N Y Acad Sci. 2002 Apr;959:82-92 [